SolarWindow (WNDW) S-1/A 23 Apr 18 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Feb. 28, 2018
Document And Entity Information
Entity Registrant Name	SolarWindow Technologies, Inc.
Entity Central Index Key	1,071,840
Document Type	S-1/A
Document Period End Date	Feb. 28, 2018
Amendment Flag	true
AmendmentDescription	Amendment description
Current Fiscal Year End Date	--08-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Document Fiscal Year Focus	2,018

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Feb. 28, 2018	Aug. 31, 2017	Aug. 31, 2016
Current assets
Cash and cash equivalents	$ 1,841,672	$ 670,853	$ 2,509,215
Deferred research and development costs	101,829	91,204	349,302
Prepaid expenses and other current assets	69,194	16,698	15,752
Total current assets	2,012,695	778,755	2,874,269
Equipment, net of accumulated depreciation of $53,181 and $39,255, respectively	47,717	52,953	21,331
Total assets	2,060,412	831,708	2,895,600
Current liabilities
Accounts payable	148,296	230,184	184,743
Interest payable to related party			66,401
Bridge note payable to related party, net of discount of $74,702			525,298
Convertible promissory note payable to related party			18,146
Total current liabilities	148,296	230,184	794,588
Bridge note payable to related party	600,000	600,000
Convertible promissory note payable to related party, net of discount of $413,377 and $1,650,120, respectively	2,085,238	2,586,623	1,349,880
Interest payable to related party	1,263,124	1,046,377	669,244
Total long term liabilities	3,948,362	4,233,000	2,019,124
Total liabilities	4,096,658	4,463,184	2,813,712
Commitments and contingencies
Stockholders' equity (deficit)
Preferred stock: $0.10 par value; 1,000,000 shares authorized, no shares issued and outstanding
Common stock: $0.001 par value; 300,000,000 shares authorized, 34,329,691 and 28,500,221 shares issued and outstanding at August 31, 2017 and 2016, respectively	36,251	34,330	28,500
Additional paid-in capital	41,145,870	35,363,946	33,729,715
Retained deficit	(43,218,367)	(39,029,752)	(33,676,327)
Total stockholders' equity (deficit)	(2,036,246)	(3,631,476)	81,888
Total liabilities and stockholders' equity (deficit)	$ 2,060,412	$ 831,708	$ 2,895,600

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Feb. 28, 2018	Aug. 31, 2017	Aug. 31, 2016
Current assets
Equipment, net of accumulated depreciation	$ 60,997	$ 53,181	$ 39,255
Current liabilities
Bridge note payable, Discount			74,702
Convertible notes payable, Discount	$ 914,762	$ 413,377	$ 1,650,120
Stockholders' equity
Preferred stock, par value	$ 0.10	$ 0.10	$ 0.10
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Common stock, shares issued	36,250,544	34,329,691	28,500,221
Common stock, shares outstanding	36,250,544	34,329,691	28,500,221

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2018	Feb. 28, 2017	Feb. 28, 2018	Feb. 28, 2017	Aug. 31, 2017	Aug. 31, 2016
Consolidated Statements Of Operations
Revenue
Operating expense
Selling, general and administrative	615,467	606,719	2,456,693	1,651,065	2,779,325	2,318,443
Research and product development	523,532	279,493	942,295	517,280	950,470	822,922
Total operating expense	1,138,999	886,212	3,398,988	2,168,345	3,729,795	3,141,365
Loss from operations	(1,138,999)	(886,212)	(3,398,988)	(2,168,345)	(3,729,795)	(3,141,365)
Other income (expense)
Interest expense	(122,731)	(76,127)	(216,747)	(152,465)	(312,185)	(308,983)
Accretion of debt discount	(227,733)	(323,932)	(572,880)	(687,991)	(1,311,445)	(2,335,954)
Change in fair value of derivative liability						1,714,395
Loan conversion inducement expense						(565,406)
Total other income (expense)	(350,464)	(400,059)	(789,627)	(840,456)	(1,623,630)	(1,495,948)
Net loss	$ (1,489,463)	$ (1,286,271)	$ (4,188,615)	$ (3,008,801)	$ (5,353,425)	$ (4,637,313)
Basic and Diluted Loss per Common Share	$ (0.04)	$ (0.04)	$ (0.12)	$ (0.11)	$ (0.17)	$ (0.17)
Weighted average number of common shares outstanding - basic and diluted	36,135,080	28,666,741	35,743,320	28,615,533	31,299,979	27,295,540

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-In Capital	Retained Deficit	Total
Beginning Balance, Shares at Aug. 31, 2015	26,572,615
Beginning Balance, Amount at Aug. 31, 2015	$ 26,572	$ 26,144,117	$ (29,039,014)	$ (2,868,325)
Stock based compensation related to restricted stock issuance, Shares	90,000
Stock based compensation related to restricted stock issuance, Amount	$ 90	337,410		337,500
Exercise of stock options, Shares	282,106
Exercise of stock options, Amount	$ 282	(282)
February 2016 Private Placement units issued, Shares	618,000
February 2016 Private Placement units issued, Amount	$ 619	2,480,587		2,481,206
February 2016 Private Placement derivative liability at inception		(1,714,395)		(1,714,395)
June 2016 Private Placement units issued, Shares	937,500
June 2016 Private Placement units issued, Amount	$ 937	2,999,063		3,000,000
Stock based compensation due to common stock purchase options		308,763		308,763
Discount on convertible promissory note due to detachable warrants		3,008,812		3,008,812
Discount on convertible promissory note due to beneficial conversion feature		165,640		165,640
Net loss			(4,637,313)	(4,637,313)
Ending Balance, Shares at Aug. 31, 2016	28,500,221
Ending Balance, Amount at Aug. 31, 2016	$ 28,500	33,729,715	(33,676,327)	81,888
Stock based compensation due to common stock purchase options		199,599		199,599
July 2017 Private Placement units issued, Shares	300,000
July 2017 Private Placement units issued, Amount	$ 300	689,700		690,000
Stock based compensation related to stock issuances, Shares	138,904
Stock based compensation related to stock issuances, Amount	$ 139	448,463		448,602
Exercise of warrants for cash, Shares	129,000
Exercise of warrants for cash, Amount	$ 129	301,731		301,860
Exercise of warrants on a cashless basis, Shares	5,215,046
Exercise of warrants on a cashless basis, Amount	$ 5,215	(5,215)
Exercise of stock options on a cashless basis, Shares	46,520
Exercise of stock options on a cashless basis, Amount	$ 47	(47)
Net loss			(5,353,425)	(5,353,425)
Ending Balance, Shares at Aug. 31, 2017	34,329,691
Ending Balance, Amount at Aug. 31, 2017	$ 34,330	35,363,946	(39,029,752)	(3,631,476)
Stock based compensation due to common stock purchase options		874,454		874,454
Stock based compensation related to stock issuances, Shares	210,000
Stock based compensation related to stock issuances, Amount	$ 210	1,022,490		1,022,700
Exercise of warrants for cash, Shares	82,500
Exercise of warrants for cash, Amount	$ 83	257,167		257,250
Exercise of warrants on a cashless basis, Shares	665,703
Exercise of warrants on a cashless basis, Amount	$ 665	(665)
Exercise of stock options on a cashless basis, Shares	141,050
Exercise of stock options on a cashless basis, Amount	$ 141	(141)
September 2017 Private Placement units issued, Shares	821,600
September 2017 Private Placement units issued, Amount	$ 822	2,554,354		2,555,176
Discount on convertible promissory note due to warrant modifications		1,074,265		1,074,265
Net loss			(4,188,615)	(4,188,615)
Ending Balance, Shares at Feb. 28, 2018	36,250,544
Ending Balance, Amount at Feb. 28, 2018	$ 36,251	$ 41,145,870	$ (43,218,367)	$ (2,036,246)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended		12 Months Ended
	Feb. 28, 2018	Feb. 28, 2017	Aug. 31, 2017	Aug. 31, 2016
Cash flows from operating activities
Net loss	$ (4,188,615)	$ (3,008,801)	$ (5,353,425)	$ (4,637,313)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation	7,817	5,773	13,925	11,504
Stock based compensation expense	1,897,154	530,562	648,201	646,263
Change in fair value of derivative liability				(1,714,395)
Loan conversion inducement expense				565,406
Accretion of debt discount	572,880	687,991	1,311,445	2,335,954
Changes in operating assets and liabilities:
Decrease (increase) in deferred research and development costs	(10,625)	155,286	258,098	(243,167)
Decrease (increase) in prepaid expenses and other current assets	(52,496)	(9,075)	(946)	5,400
Increase (decrease) in accounts payable	(81,888)	(82,261)	45,441	87,305
Increase (decrease) in interest payable	216,747	151,012	310,732	308,983
Net cash flows from operating activities	(1,639,026)	(1,569,513)	(2,766,529)	(2,634,060)
Cash flows from investing activity
Purchase of equipment	(2,581)	(45,547)	(45,547)	(2,300)
Net cash flows from investing activity	(2,581)	(45,547)	(45,547)	(2,300)
Cash flows from financing activities
Proceeds from the issuance of equity securities	2,812,426		991,860	4,367,100
Repayment of promissory note		(18,146)	(18,146)
Proceeds from promissory notes				550,010
Net cash flows from financing activities	2,812,426	(18,146)	973,714	4,917,110
Change in cash and cash equivalents	1,170,819	(1,633,206)	(1,838,362)	2,280,750
Cash and cash equivalents at beginning of period	670,853	2,509,215	2,509,215	228,465
Cash and cash equivalents at end of period	1,841,672	876,009	670,853	2,509,215
Supplemental disclosure of cash flow information:
Interest paid in cash		1,453	1,453
Income taxes paid in cash
Supplemental disclosure of non-cash transactions:
Debt discount recorded for value of warrants issued and/or modified				3,008,812
Debt discount recorded for beneficial conversion feature				165,640
Common stock issued for conversion of note payable				548,700
Derivative liability from the sale of equity securities				$ 1,714,395
Discount on convertible promissory note due to to warrant modifications	$ 1,074,265

Organization and Going Concern

Organization and Going Concern	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Notes to Financial Statements
NOTE 1 - Organization and Going Concern	Basis of Presentation The unaudited financial statements of SolarWindow Technologies, Inc. (the “ Company GAAP KEC New Energy Solar Organization SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998, under the name “Octillion Corp.” On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. Effective as of March 9, 2015, the Company amended its Articles of Incorporation to change its name to SolarWindow Technologies, Inc. to align the company name with its brand identity. The Company’s ticker symbol changed to WNDW. The Company has been developing two sustainable electricity generating systems. These novel technologies are branded as SolarWindow™ and MotionPower™. On March 2, 2015, the Company announced its exclusive focus on SolarWindow™. The Company’s SolarWindow™ technology harvests light energy from the sun and artificial sources to generate electricity from a transparent coating of organic photovoltaic solar cells applied to glass or plastics, creating a “photovoltaic” effect. Photovoltaics are best known as “solar panels” providing a method to generate electricity using solar cells to convert energy from the sun into a flow of electrons. Conventional PV power is generated by solar modules composed of interconnected mono- or poly-crystalline cells containing PV and electricity-conducting materials. These materials are usually opaque (i.e., not see-through) and only effectively generate electricity with sun light. The Company’s researchers have replaced these materials with a very thin layer of specially developed compounds that allow our SolarWindow™ technology to remain see-through or “transparent,” while generating electricity when exposed to either sun or artificial light. The Company’s SolarWindow™ research and product development programs involve ongoing efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by its contract engineers, scientists, and consultants. The Company’s activities are subject to significant risks and uncertainties, including, but not limited to, the Company’s failure to secure, on a timely basis, adequate additional funding to commercialize its SolarWindow™ technology or the development of a similar technology and products, by existing or potential future competitors, who may gain earlier market entry or greater market acceptance than the Company’s technology and products. Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. Management is currently assessing the impact the adoption of ASU 2017-09 will have on the Company’s Consolidated Financial Statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)”, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance is effective for our current fiscal year. The adoption of ASU 2016-09 did not have a material impact on the consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for our current fiscal year. The adoption of ASU 2015-17 did not have a material impact on the consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements. Going Concern The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. Due to the “start-up” nature of our business, we expect to incur losses as we continue development of our products and technologies. As of February 28, 2018, the Company has incurred recurring operating losses since inception of $43,218,367. As of February 28, 2018, the Company had approximately $1,841,672 of cash on hand and current liabilities of $148,296. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business. As of the date of filing of the Company’s most recent Form 10-K on November 22, 2017, based on management’s assessment, the Company had sufficient cash to meet its funding requirements for the next twelve months. However, currently, based upon the Company’s near term anticipated level of operations and expenditures, management believes that cash on hand should be sufficient to enable the Company to continue operations through November 2018 or approximately seven months from the date of this quarterly report. In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements. The Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company expects to seek additional funding through private equity or convertible debt. If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company’s business, operating results, financial condition and prospects. In particular, the Company may be required to delay; reduce the scope of or terminate its research and development programs; sell rights to its SolarWindow™ technology and/or MotionPower™ technology, or other technologies or products based upon these technologies; or license the rights to these technologies or products on terms that are less favorable to the Company than might otherwise be available.	Organization SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998, under the name “Octillion Corp.” On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. Effective as of March 9, 2015, the Company amended its Articles of Incorporation to change its name to SolarWindow Technologies, Inc. to align the company name with its brand identity. The Company’s ticker symbol changed to WNDW. The Company has been developing two sustainable electricity generating systems. These novel technologies are branded as SolarWindow™ and MotionPower™. On March 2, 2015, the Company announced its exclusive focus on SolarWindow™. The Company’s SolarWindow™ technology provides the ability to harvest light energy from the sun and artificial sources and generate electricity from a transparent, coating of organic photovoltaic solar cells, applied to glass and plastics, thereby creating a “photovoltaic” effect. Photovoltaics are best known as a method for generating electric power by using solar cells to convert energy from the sun into a flow of electrons. Typically, conventional PV power is generated by making use of solar modules composed of a number of cells containing PV and electricity-conducting materials. These materials are usually opaque (i.e., not see-through) and only effectively generate electricity with sun light. The Company’s researchers have replaced these materials with compounds that allow our SolarWindow™ technology to remain see-through or “transparent,” while generating electricity when exposed to either sun or artificial light. The Company’s SolarWindow™ product development programs involve ongoing product development efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by its contract engineers, scientists, and consultants. The Company’s activities are subject to significant risks and uncertainties, including, but not limited to, the Company’s failure to secure, on a timely basis, adequate additional funding to commercialize the Company’s SolarWindow™ technology or the development of a similar technology and products, by existing or potential future competitors, that may gain earlier market entry or greater market acceptance than the Company’s technology and products. Going Concern The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. Due to the “start-up” nature of our business, we expect to incur losses as we continue development of our products and technologies. These are conditions that initially indicated substantial doubt about the Company’s ability to continue as a going concern. Over the past year, the Company has been funded through the sale of equity securities. As of August 31, 2017, the Company had approximately $670,853 of cash. On September 29, 2017, the Company completed a private placement with a group of private investors, whereby the Company received proceeds of $2,555,176 from the sale of common stock and warrants. From September 9, 2017 through October 31, 2017, the Company received $248,000 upon the exercise of 80,000 Series O Warrants. On November 3, 2017, the Company entered into the Third Amendment to the 2013 Bridge Loan Agreement with the Investor pursuant to which the Company and the Investor amended the 2013 Note (with a principal balance of $3,000,000) to extend the maturity date to December 31, 2019. On November 3, 2017, the Company entered into the Third Amendment to the 2015 Bridge Loan Agreement with the Investor pursuant to which the Company and the Investor amended the March 2015 loan (with a principal balance of $600,000) to extend the maturity date to December 31, 2019. The Company believes that, as a result of the recent financings and note maturity date extensions, it currently has sufficient cash to meet its funding requirements over the next year and these events alleviate the conditions which initially indicated substantial doubt about the Company's ability to continue as a going concern. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company expects to seek to obtain additional funding through private equity or convertible debt. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Aug. 31, 2017
Notes to Financial Statements
NOTE 2 - Summary of Significant Accounting Policies	Principles of Consolidation Kinetic Energy Corporation (“KEC”) was incorporated on June 19, 2008, in the State of Nevada and holds the patents related to the Company’s MotionPower™ technology. The Company’s business activities related to the MotionPower™ technology are conducted through KEC. New Energy Solar was incorporated on February 9, 2009, in the State of Florida and entered into agreements with The University of South Florida Research Foundation (“USF”) to sponsor research related to the Company’s SolarWindow™ technology. On February 18, 2015, the Company terminated the license agreement entered into with USF which originated on June 21, 2010. These consolidated financial statements presented are those of the Company and its wholly owned subsidiaries, KEC, and New Energy Solar. All significant intercompany balances and transactions have been eliminated. Estimates The preparation of the Company’s consolidated financial statements requires management to make estimates and use assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. On an on-going basis, the Company evaluates its estimates. Actual results and outcomes may differ materially from these estimates and assumptions. Cash and Cash Equivalents Cash and cash equivalents includes highly liquid investments with original maturities of three months or less. The Company has amounts deposited with financial institutions in excess of federally insured limits. Property, Plant, and Equipment Fixed assets are carried at cost, less accumulated depreciation and amortization. Major improvements are capitalized, while repair and maintenance are expensed when incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. Depreciation is computed on a straight-line basis over estimated useful lives of the related assets. The estimated useful lives of depreciable assets are: Estimated Useful Lives Office equipment 3-5 years Furniture & equipment 5 - 7 years Fair Value Measurement The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 1 inputs. Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 2 inputs. Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 3 inputs. Fair Value of Financial Instruments The carrying value of cash and cash equivalents, accounts payable and interest payable approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of the Company’s notes payable due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Research and Development Research and development costs represent costs incurred to develop the Company’s technology, including salaries and benefits for research and development personnel, allocated overhead and facility occupancy costs, supplies, equipment purchase and repair and other costs. Research and development costs are expensed when incurred, except for nonrefundable advance payments for future research and development activities which are capitalized and recognized as expense as the related services are performed. Stock-Based Compensation The Company measures all employee stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company has granted stock options with performance conditions to certain nonemployee consultants. At each reporting date, the Company evaluates whether the achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon the assessment of achievement of each performance condition or the occurrence of the event which will trigger the options to vest. The Company uses the Black-Scholes-Merton formula to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes-Merton formula requires management to make assumptions regarding the option lives, expected volatility, and risk free interest rates. See “NOTE 6 – Common Stock and Warrants” and “NOTE 7 - Stock Options” for additional information on the Company’s stock-based compensation plans. Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively. Segment Reporting The Company’s business is considered to be operating in one segment based upon the Company’s organizational structure, the way in which the operations are managed and evaluated, the availability of separate financial results and materiality considerations. Net Income (Loss) Per Share The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The computation of diluted net income per share does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on earnings per share. Therefore, when calculating EPS if the Company experienced a loss, there is no inclusion of dilutive securities as their inclusion in the EPS calculation is antidilutive. Furthermore, options and warrants will have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options or warrants (they are in the money). See “NOTE 8 - Net Loss Per Share” for further discussion. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“ FASB ASU In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. The Company has determined that the adoption of ASU 2015-17 will currently have no impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.

Debt

Debt	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Notes to Financial Statements
NOTE 3 - Debt	As of February 28, 2018 and August 31, 2017, the Company had the following outstanding debt balances: Issue Maturity Debt Interest Date Date Principal Discount Balance Payable As of February 28, 2018: March 2015 Loan as amended 3/4/2015 12/31/2019 $ 600,000 $ - $ 600,000 $ 146,747 2013 Note as amended 10/7/2013 12/31/2019 3,000,000 (914,762 ) 2,085,238 1,116,377 $ 3,600,000 $ (914,762 ) $ 2,685,238 $ 1,263,124 As of August 31, 2017: March 2015 Loan as amended 3/4/2015 12/31/2017 $ 600,000 $ - $ 600,000 $ 113,465 2013 Note as amended 10/7/2013 12/31/2017 3,000,000 (413,377 ) 2,586,623 932,912 $ 3,600,000 $ (413,377 ) $ 3,186,623 $ 1,046,377 March 2015 Loan as Amended On March 4, 2015, the Company entered into a Bridge Loan Agreement with 1420468 Alberta Ltd. (which has since been merged with and into Kalen Capital Corporation (the “Investor”)). Pursuant the Bridge Loan Agreement, the Company borrowed $600,000 at an annual interest rate of 7% (the “ March 2015 Loan On November 3, 2017, the Company entered into the Third Amendment related to the March 2015 Loan pursuant to which the Company and the Investor amended the March 2015 loan to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5%. During the three months ended February 28, 2018 and 2017, the Company recognized $18,846 and $11,690, respectively, of interest expense. During the six months ended February 28, 2018 and 2017, the Company recognized $33,282 and $23,306, respectively, of interest expense. During the three and six months ended February 28, 2018, the Company recognized no debt discount accretion. During the three and six months ended February 28, 2017, the Company recognized debt discount accretion of $18,982 and $74,702, respectively. 2013 Note as Amended On October 7, 2013, the Company sold to the Investor an unsecured Convertible Promissory Note (the “ 2013 Note On November 3, 2017, the Company entered into the Third Amendment related to the 2013 Note pursuant to which the Company and the Investor amended the 2013 Note to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5% and all outstanding warrants held by the Investor had their maturity date extended to December 31, 2022, as described below, resulting in an additional debt discount of $1,074,265 as of November 3, 2017. The modification did not result in a gain or loss due to the related party nature of the transaction. The maturity date of the remaining Series M Warrant to purchase 246,000 shares of common stock was extended from December 31, 2020 to December 31, 2022. The Company recorded $82,656 as a debt discount to recognize the increase in value for the extension of the expiration date. The maturity date of the Series N Warrant to purchase 767,000 shares of common stock was extended from December 31, 2020 to December 31, 2022. The Company recorded $327,509 as a debt discount to recognize the increase in value for the extension of the expiration date. The maturity date of the Series P Warrant to purchase 213,500 shares of common stock was extended from April 30, 2018 to December 31, 2022. The Company recorded $348,219 as a debt discount to recognize the increase in value for the extension of the expiration date. The maturity date of the Series R Warrant to purchase 468,750 shares of common stock was extended from June 20, 2021 to December 31, 2022. The Company recorded $295,781 as a debt discount to recognize the increase in value for the extension of the expiration date. The maturity date of the Series S-A Warrant to purchase 300,000 shares of common stock was extended from July 24, 2022 to December 31, 2022. The Company recorded $20,100 as a debt discount to recognize the increase in value for the extension of the expiration date. Interest expense related to the 2013 Note, as amended, amounted to $103,885 and $64,437 during the three months ended February 28, 2018 and 2017, respectively. Interest expense amounted to $183,465 and $128,473 during the six months ended February 28, 2018 and 2017, respectively. Accretion of the debt discount related to the 2013 Note as amended amounted to $227,733 and $304,950 during the three months ended February 28, 2018 and 2017, respectively and $572,880 and $613,289 during the six months ended February 28, 2018 and 2017, respectively. The remaining debt discount related to warrant expiration date extensions totals $914,762 and will be amortized through December 31, 2019.	December 7, 2015, $550,000 Bridge Loan On December 7, 2015, the Company entered into a Bridge Loan Agreement (the “ December 2015 Loan Agreement Series M Warrant The debt discount attributable to the warrants and beneficial conversion feature amounted to $458,777 and discount was accreted through March 31, 2016. On March 31, 2016, upon the conversion of $548,700 of the principal owed under the December 2015 Loan Agreement, the Investor received 177 PPM Units pursuant to the March 2016 Private Placement (defined below) resulting in a remaining balance of $18,146. The remaining balance was evidenced by a new promissory note (the “ March 2016 Note The PPM Units issued in exchnge for the conversion of principal owed under the December 2015 Loan Agreement contained terms that were more beneficial to the Investor resulting in the Company recognizing a loan conversion inducement expense of $36,176 related to the common stock issued and $529,230 related to the warrant component of the PPM Units (i.e., the Series O Warrant and Series P Warrant as defined below under Note 4). During the year ended August 31, 2017 and 2016, the Company recognized $695 and $17,604, respectively, of interest expense. Accretion related to the debt discount for the December 2015 Loan Agreement amounted to $0 and $458,777 during the years ended August 31, 2017 and 2016, respectively. March 4, 2015, $600,000 Bridge Loan On March 4, 2015, the Company entered into a Bridge Loan Agreement (the “ Bridge Loan Agreement March 2015 Loan Series L Warrant The debt discount attributable to the relative fair value of the Series L Warrant issued with the March 2015 Loan, amounted to $299,750 and was accreted over the original term of the March 2015 Loan through September 4, 2015. On December 7, 2015, The Investor agreed to extend the maturity date of the March 2015 Loan from September 4, 2015 to December 31, 2016 and extend the expiration date of the Series L Warrant from March 4, 2020 to December 7, 2020. As consideration the Company issued The Investor a Series M Stock Purchase Warrant to purchase 100,000 shares of the Company’s common stock through December 7, 2020, at an exercise price of $2.34 per share. As a result, the Company recognized an additional debt discount for the fair value of the Series M Stock Purchase Warrant and extension of the expiration date of the Series L Warrant amounting to $205,800 and $33,000, respectively. On January 5, 2017, the Company and the The Investor entered into the Second Amendment to Bridge Loan Agreement extending the maturity date of the March 2015 Loan from December 31, 2016 to December 31, 2017. No consideration was exchanged for this extension in the maturity date. On November 3, 2017, the Company entered into the Third Amendment to the 2015 Bridge Loan Agreement with the Investor pursuant to which the Company and the Investor amended the March 2015 loan to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5% and all outstanding warrants held by the Investor had their maturity date extended to December 31, 2022. During the years ended August 31, 2017 and 2016, the Company recognized $47,832 and $44,742, respectively, of interest expense. Accretion related to the debt discount for the March 2015 Loan, Series L Warrant and Series M Warrant amounted to $74,702 and $170,614 during the years ended August 31, 2017 and 2016, respectively. October 7, 2013, $3,000,000 Convertible Promissory Note On October 7, 2013, the Company entered into a Bridge Loan Agreement (the “ 2013 Loan Agreement 2013 Note Series I Warrant Series J Warrant Series K Warrant On November 10, 2014, the Company entered into an Amended Bridge Loan Agreement (the “ 2015 Loan Agreement In order to induce the Investor to enter into the 2015 Loan Agreement and extend the maturity date to December 31, 2015, the Company issued a Series J Warrant to purchase 3,110,378 shares of its common stock at an exercise price of $1.12 and a Series K Warrant to purchase 3,110,378 shares of its common stock at an exercise price of $1.20. Each of the Series J Warrant and Series K Warrant was initially exercisable through November 9, 2019. As a result of the modification (which did not result in a gain or loss due to the related party nature of the transaction), the fair value of the Warrant amounting to $3,629,309 (limited to the $3,000,000 face value of the note) was recognized as a debt discount as of November 10, 2014. On December 31, 2015, the Company entered into a Second Amended Bridge Loan Agreement (the “ 2015 Second Amended Loan Agreement On November 3, 2017, the Company entered into the Third Amendment to the 2013 Bridge Loan Agreement with the Investor pursuant to which the Company and the Investor amended the 2013 Note to extend the maturity date to December 31, 2019. As consideration for the note extension, the interest rate was increased to 10.5% and all outstanding warrants held by the Investor had their maturity date extended to December 31, 2022. As consideration for the Investor agreeing to extend the 2013 Note maturity date to December 31, 2017, the Company issued a Series N Warrant and extended the maturity date of certain of the Investor’s existing warrants, as described below, resulting in an additional debt discount of $2,476,875 as of December 31, 2015. The modification did not result in a gain or loss due to the related party nature of the transaction. The Company issued a Series N Warrant to purchase 767,000 shares of common stock at an exercise price of $3.38 through December 31, 2020. The fair value of the Series N Warrant was $2.102 per share, or $1,612,234 and the resulting debt discount is being accreted through December 31, 2017. The maturity date of the Series I Warrant to purchase 921,875 shares of common stock was extended from October 6, 2018 to December 31, 2020. The Company recorded $233,234 as a debt discount to recognize the increase in value for the extension of the expiration date. The maturity date of the Series J Warrant to purchase 3,110,378 shares of common stock was extended from November 9, 2019 to December 31, 2020. The Company recorded $304,817 as a debt discount to recognize the increase in fair value for the extension of the expiration date which is being accreted through December 31, 2017. The maturity date of the Series K Warrant to purchase 3,110,378 shares of common stock was extended from November 9, 2019 to December 31, 2020. The Company recorded $326,590 as a debt discount to recognize the increase in fair value for the extension of the expiration date which is being accreted through December 31, 2017. Interest expense related to the 2013 Loan Agreement, as amended, amounted to $263,668 and $246,637 during the years ended August 31, 2017 and 2016, respectively. Accretion of the debt discount related to the 2013 Loan Agreement as amended amounted to $1,236,743 and $1,706,563 during the years ended August 31, 2017 and 2016, respectively. The remaining debt discount related to the Series N Warrants and Series I, J and K Warrant expiration date extensions totals $413,377 and will be amortized through December 31, 2017. Principal maturities for notes payable for the years ending August 31 are as follows (See “NOTE 11 – Subsequent Events” below): 2018 - 2019 - 2020 3,600,000 Total $ 3,600,000

Private Placements

Private Placements	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Notes to Financial Statements
NOTE 4 - Private Placements	September 2017 Private Placement On September 11, 2017, the Company initiated and on September 29, 2017, completed a self-directed offering of 821,600 units at a price of $3.11 per unit for $2,555,176 in aggregate proceeds (the “ September 2017 Private Placement The relative fair value of the common stock was estimated to be $1,540,000. The relative fair value of the Series S Warrants was estimated to be $1,015,000 as determined based on the relative fair value allocation of the proceeds received. The Series S Warrants were valued using the Black-Scholes option pricing model using the following variables: market price of common stock - $3.95 per share; estimated volatility – 77.96%; 5-year risk free interest rate – 1.71%; expected dividend rate - 0% and expected life - 5 years.	July 2017 Private Placement On July 24, 2017, the Company completed a self-directed offering of 300,000 units at a price of $2.30 per unit for $690,000 in aggregate proceeds (the “ July 2017 Private Placement Series S-A Warrant The relative fair value of the common stock was estimated to be $414,000. The relative fair value of the Series S-A Warrants was estimated to be $276,000 as determined based on the relative fair value allocation of the proceeds received. The Series S-A Warrants were valued using the Black-Scholes option pricing model using the following variables: market price of common stock - $3.20 per share; estimated volatility – 76.13%; 5-year risk free interest rate – 1.83%; expected dividend rate - 0% and expected life - 5 years. June 2016 Private Placement On June 20, 2016, the Company completed a self-directed offering of 937,500 units at a price of $3.20 per unit for $3,000,000 in aggregate proceeds (the “ June 2016 Private Placement Series Q Warrant Series R Warrant The relative fair value of the common stock was estimated to be $1,338,000. The relative fair value of the Series Q Warrants and Series R Warrants was estimated to be $783,000 and $879,000, respectively, as determined based on the relative fair value allocation of the proceeds received. March 2016 Private Placement Beginning on February 18, 2016 and closing on March 31, 2016, the Company completed an offering pursuant to a Private Placement Memorandum dated February 16, 2016 (the “ March 2016 Private Placement PM Units Series O Warrant Series P Warrant The terms of the March 2016 Private Placement provided for a onetime reset adjustment (the “Reset Adjustment”) such that if, within 6 months from the March 2016 Private Placement Termination Date, the Company sold equity securities at a price less than $3.10 per share (“Reset Price”), each of the subscribers having purchased Units in the March 2016 Private Placement would receive additional Units (the “Reset Units”) equal to the difference between the number of Units that would have been issuable to such subscribers if the price per share of common stock included in the Units was equal to the Reset Price less the number of Units actually received by such subscriber. The Reset Adjustment expired on September 30, 2016; no Reset Units were issued. The Reset Adjustment was accounted for as a derivative, measured at fair value, during the year ended August 31, 2016. The Company determined the Reset Adjustment had no value as of August 31, 2016.

Derivative Liability Related to

Derivative Liability Related to the PPM Units	12 Months Ended
	Aug. 31, 2017
Notes to Financial Statements
NOTE 5 - Derivative Liability Related to the PPM Units	The Reset Adjustment contained in the March 2016 Private Placement did not have fixed settlement provisions because the number of PPM Units issued may be adjusted higher if the Company sells securities at lower prices in the future; therefore, the Company concluded that the Reset Adjustment feature was not indexed to the Company’s stock and is to be treated as a derivative liability for accounting purposes. The accounting treatment for derivative financial instruments requires that the Company allocate a portion of the equity proceeds to the derivative for an amount equal to its initial fair value. Subsequently, on each reporting date, the fair value of the derivative is measured with changes in value recorded to other income/expense. In determining the fair value of the derivative liabilities, the Company used a Monte Carlo simulation at the date the instrument was issued and at each quarter end until the termination date of the Reset Adjustment on September 30, 2016. A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s derivative liability that is categorized within Level 3 of the fair value hierarchy during the year ended August 31, 2016 as follows: Common stock issuable upon exercise of Series O Warrants 618,000 Common stock issuable upon exercise of Series P Warrants 309,000 Stock price $3.13 - $4.19 Volatility (Annual) 80% - 83% Strike price $3.10, Series O Warrants; $3.70, Series P Warrants Risk-free rate 0.71% - 0.80% Series O Warrants; 0.71% - 0.79%, Series P Warrants Term 1.4 – 1.7 years Series O Warrants; 2.1 - 2.2 years, Series P Warrants Probability of Reset Adjustment 0% - 100% As of August, 31, 2016, as a result of the June 2016 Private Placement, the Company had no plans to raise capital prior to the expiration date of the Reset Adjustment. As a result, the Company determined that the Reset Adjustment had no value as of August 31, 2016 resulting in the reclassification of the derivative liability balance to additional paid-in capital. The following table sets forth the Company’s derivative liabilities that were accounted for at fair value on a recurring basis categorized within Level 3 of the fair value hierarchy during the year ended August 31, 2016: Balance at August 31, 2015 Initial valuation of derivative liabilities upon issuance of new securities during the period Increase (decrease) in fair value of derivative liabilities Balance at August 31, 2016 Warrant liability $ - $ 1,714,395 $ (1,714,395 ) $ -

Common Stock and Warrants

Common Stock and Warrants	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Notes to Financial Statements
NOTE 6 - Common Stock and Warrants	Common Stock At February 28, 2018, the Company had 300,000,000 authorized shares of common stock with a par value of $0.001 per share, 36,250,544 shares of common stock outstanding and 1,035,197 shares reserved for issuance under the Company’s 2006 Long-Term Incentive Plan (the “ 2006 Plan During the six months ended February 28, 2018, we entered into the following securities related transactions: · On September 29, 2017, the Company completed the September 2017 Private Placement of 821,600 units at a price of $3.11 per unit for $2,555,176 in aggregate proceeds. Each unit consisted of one share of common stock and one Series S Stock Purchase Warrant to purchase one (1) share of common stock at an exercise price of $3.42 per share through September 29, 2022. The warrants may be exercised on a cashless basis (See “NOTE 3 – Private Placements”). · On November 21, 2017 each director was granted 40,000 shares of common stock for a total issuance of 160,000 shares of common stock valued at $4.87 per share, the fair market value of our common stock on the date of issuance. Additionally, on November 21, the Company issued Jatinder Bhogal, Director, an additional 50,000 shares valued at $4.87 per share. 75% of the 210,000 issued shares are subject to a one-year lock-up. · From September 6, 2017 through October 30, 2017, holders of our Series O Warrants exercised 80,000 warrants at an exercise price of $3.10 per share resulting in $248,000 to the Company and the issuance of 80,000 shares of common stock. · John Conklin, the Company’s President & CEO, exercised 150,000 stock purchase options on a cashless basis resulting in the issuance of 80,110 shares of common stock. · Alastair Livesey, a Company Director, exercised 36,667 stock purchase options on a cashless basis resulting in the issuance of 19,067 shares of common stock. · Three other individuals exercised a total of 90,000 stock purchase options on a cashless basis resulting in the issuance of 41,873 shares of common stock. · On September 7, 2017, the Investor exercised their outstanding Series Q Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 189,940 shares of common stock. · On September 7, 2017, a third party exercised their outstanding Series Q Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 189,940 shares of common stock. · On December 28, 2017, a third party exercised their outstanding Series R Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 285,823 shares of common stock. · Three holders of our Series P Warrants exercised 2,500 warrants at an exercise price of $3.70 per share resulting in $9,250 to the Company and the issuance of 2,500 shares of common stock. Warrants Each of the Company’s warrants outstanding entitles the holder to purchase one share of the Company’s common stock for each warrant share held. Other than the Series O Warrants and Series P Warrants, all of the following warrants may be exercised on a cashless basis. A summary of the Company’s warrants outstanding and exercisable as of February 28, 2018 and August 31, 2017 is as follows: Shares of Common Stock Issuable from Warrants Outstanding as of Weighted Average February 28, August 31, Exercise Description 2018 2017 Price Expiration Series M 246,000 246,000 $ 2.34 December 31, 2022 Series N 767,000 767,000 $ 3.38 December 31, 2022 Series O - 618,000 $ 3.10 October 31, 2017 Series P 306,500 309,000 $ 3.70 April 30, 2018 Series Q - 937,500 $ 3.20 December 31, 2022 Series R 468,750 937,500 $ 4.00 December 31, 2022 Series S-A 300,000 300,000 $ 2.53 December 31, 2022 Series S 821,600 - $ 3.42 September 29, 2022 Total 2,909,850 4,115,000	Common Stock At August 31, 2017, the Company had 300,000,000 authorized shares of common stock with a par value of $0.001 per share, 34,329,691 shares of common stock outstanding and 2,072,580 shares reserved for issuance under the Company’s 2006 Long-Term Incentive Plan (the “ 2006 Plan During the year ended August 31, 2017, we entered into the following securities related transactions: · On July 24, 2017, the Company completed the July 2017 Private Placement of 300,000 units at a price of $2.30 per unit for $690,000 in aggregate proceeds. Each unit consisted of one share of common stock and one Series S-A Warrant to purchase one (1) share of common stock at an exercise price of $2.53 per share through July 24, 2022. The warrants may be exercised on a cashless basis. All of the units of the July 2017 Private Placement were purchased by the Investor (See “NOTE 4 – Private Placements”). · On July 7, 2017, the Company finalized and executed two consulting agreements with third parties to provide business development services. The terms and conditions of each consulting agreement are similar and provide for combined compensation of $26,000 per month in cash and the grant of 1,500,000 common stock purchase options which vest upon the attainment of certain milestones and upon Board approval. During August 2017, the Company issued 13,622 shares of common stock, valued at $40,000 (based on the closing price of the Company’s stock on the date transferred), to pay consulting fees incurred under the agreements. · On July 7, 2017, the Company issued 5,282 shares of common stock in exchange for services valued at $15,000 (based on the closing price of the Company’s stock on the date transferred). · In June 2017, the Investor exercised 129,000 Series M Warrants at an exercise price of $2.34 per share and paid the Company $301,860 in exchange for 129,000 shares of common stock. · On March 2, 2017, the Investor exercised all Series I, J, K and L Warrants (7,642,631 shares in total) on a cashless basis and received 5,215,046 shares of common. · On November 15, 2016 each director was issued 40,000 shares of common stock for a total issuance of 120,000 shares of common stock valued at $3.28 per share, the fair market value of our common stock on the date of issuance. · issued 46,520 shares of common stock upon the cashless exercise of 130,000 options. During the year ended August 31, 2016, the Company had the following common stock related transactions: · issued 282,106 shares of common stock upon the cashless exercise of 556,667 options. · issued 30,000 shares of common stock on January 5, 2016 to each of the Company’s three directors pursuant to the 2006 Plan (90,000 shares total) valued at $3.75 per share, the closing price of the Company’s common stock on the day the stock was granted. · received $1,367,100 pursuant to the March 2016 Private Placement for the purchase of 441 PPM Units resulting in the issuance of 441,000 shares of common stock (See “NOTE 4 – Private Placements”). · converted loan principal of $548,700 from the December 2015 Loan Agreement in exchange for 177 PPM Units resulting in the issuance of 177,000 shares of common stock (See “NOTE 3 – Debt”). · received $3,000,000 pursuant to the June 2016 Private Placement for the purchase of 937,500 units resulting in the issuance of 937,500 shares of common stock (See “NOTE 4 – Private Placements”). Warrants Each of the Company’s warrants outstanding entitles the holder to purchase one share of the Company’s common stock for each warrant share held. Other than the Series O Warrants and Series P Warrants, all of the following warrants may be exercised on a cashless basis. A summary of the Company’s warrants outstanding and exercisable as of August 31, 2017 and 2016 is as follows: Shares of Common Stock Issuable from Warrants Outstanding as of Weighted Average August 31, August 31, Exercise Description 2017 2016 Price Expiration Series I - 921,875 $ 1.37 December 31, 2020 Series J - 3,110,378 $ 1.12 December 31, 2020 Series K - 3,110,378 $ 1.20 December 31, 2020 Series L - 500,000 $ 1.20 December 7, 2020 Series M 246,000 375,000 $ 2.34 December 31, 2020 Series N 767,000 767,000 $ 3.38 December 31, 2020 Series O 618,000 618,000 $ 3.10 October 31, 2017 Series P 309,000 309,000 $ 3.70 April 30, 2018 Series Q 937,500 937,500 $ 3.20 June 20, 2019 Series R 937,500 937,500 $ 4.00 June 20, 2021 Series S-A 300,000 - $ 2.53 July 24, 2022 Total 4,115,000 11,586,631 The Series I Warrant was issued on October 7, 2013, in connection with the 2013 Loan Agreement. On December 31, 2015, as consideration for the Investor agreeing to extend the 2013 Note maturity date to December 31, 2017, the Company extended the maturity date of the Series I Warrant from October 6, 2018 to December 31, 2020. The Series I Warrant was exercised in full and on a cashless basis on March 2, 2017 resulting in the issuance of 584,634 shares of common stock. The Series J Warrant and Series K Warrant were issued on November 10, 2014 as a condition to the Investor entering into the 2015 Loan Agreement. On December 31, 2015, as consideration for the Investor agreeing to extend the 2013 Note maturity date to December 31, 2017, the Company extended the maturity date of the Series J and K Warrants from November 9, 2019 to December 31, 2020. The Series J and K Warrant were exercised in full and on a cashless basis on March 2, 2017 resulting in the issuance of 4,293,900 shares of common stock. The Series L Warrant was issued on March 4, 2015 in connection with the March 2015 Loan. On December 7, 2015, the expiration date of the Series L Warrant was extended from March 4, 2020 to December 7, 2020. The Series L Warrant was exercised in full and on a cashless basis on March 2, 2017 resulting in the issuance of 336,512 shares of common stock. A Series M Warrant, with an exercise price of $2.34, to purchase 275,000 shares of common stock was issued on December 7, 2015 in connection with the December 2015 Loan. A Series M Warrant, with an exercise price of $2.34, to purchase 100,000 shares was issued on December 7, 2015 as an inducement for the Investor to extend the maturity date of the March 2015 Loan from September 4, 2015 to December 21, 2016. In June 2017, the Investor exercised 129,000 Series M Warrants. The Series N Warrant to purchase 767,000 shares was issued on December 31, 2015 pursuant to the 2015 Second Amended Loan Agreement as an inducement for the Investor to extend the maturity date of the 2013 Note from December 31, 2015 to December 31, 2017. The Series O and Series P Warrants were issued in connection with the March 2016 Private Placement and the Series Q and Series R Warrants were issued in connection with the June 2016 Private Placement; see “NOTE 4 – Private Placements.” The Series S-A Warrant was issued in connection with the July 2017 Private Placement; see “NOTE 4 – Private Placements.” On November 3, 2017, the term of the Series M Warrant, Series N Warrant, Series P Warrant for 213,500 shares, Series R Warrant for 468,750 shares, and Series S-A Warrant were extended to December 31, 2022, as contemplated by the Amendments described in Note 11. There are a total of approximately 2,870,739 warrants issuable pursuant to the 2013 Loan Agreement as described above under “NOTE 3 – Debt: October 7, 2013, $3,000,000 Convertible Promissory Note

Stock Options

Stock Options	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Notes to Financial Statements
NOTE 7 - Stock Options	Stock option grants pursuant to the 2006 Plan vest either immediately or over one to five years and expire ten years after the date of grant. Stockholders previously approved 5,000,000 shares for grant under the 2006 Plan, of which 1,035,197 remain available for grant, 1,290,001 have been exercised in total and 624,565 net shares issued pursuant to the exercise of vested options from inception of the 2006 Plan through February 28, 2018. All shares approved for grant and subsequently forfeited are available for future grant. The Company does not repurchase shares to fulfill the requirements of options that are exercised. The Company issues new shares when options are exercised. The 2006 Plan was approved by stockholders on February 7, 2011 and expires according to its terms on February 7, 2021. The Company employs the following key weighted-average assumptions in determining the fair value of stock options, using the Black-Scholes option pricing model and the simplified method to estimate the expected term of “plain vanilla” options: Six Months Ended February 28, 2018 2017 Expected dividend yield – – Expected stock price volatility 83.43% – 83.55% 79% - 81% Risk-free interest rate 2.27% - 2.33% 1.95% - 2.03% Expected term (in years) 7.67 5.00 - 7.67 Exercise price $4.87 - $5.35 $ 2.71 Weighted-average grant date fair-value $3.76 - $5.64 $ 1.85 A summary of the Company’s stock option activity for the six months ended February 28, 2018 and year ended August 31, 2017 and related information follows: Number of Shares Subject to Option Grants Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at August 31, 2016 720,001 3.06 Grants 1,535,000 2.71 Exercises (130,000 ) 2.62 Outstanding at August 31, 2017 2,125,001 2.84 Grants 1,263,000 5.25 Forfeitures (300,000 ) 2.90 Exercises (276,667 ) 3.30 Outstanding at February 28, 2018 2,811,334 3.87 6.79 years 5,154,075 Exercisable at February 28, 2018 215,334 4.84 8.38 years 193,975 The aggregate intrinsic value in the table above represents the total pretax intrinsic value for all “in-the-money” options (i.e. the difference between the Company’s closing stock price on the last trading day of the period covered by this report and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all in-the-money option holders exercised their vested options on February 28, 2018. The intrinsic value of the option changes based upon the fair market value of the Company’s common stock. Since the closing stock price was $5.70 on February 28, 2018 and 2,778,000 outstanding options have an exercise price below $5.70 per share, as of February 28, 2018, there is intrinsic value to the Company’s outstanding, in-the-money stock options, including 182,000 options that are exercisable and in-the-money. On November 21, 2017, the Company granted 255,000 options to directors and employees with an exercise price of $4.87. On December 27, 2017, the Company entered into an employment agreement with John Conklin pursuant to which Mr. Conklin was granted 1,008,000 stock purchase options with an exercise price of $5.35 per share, vesting at the rate of 1/48 th During the six months ended February 28, 2018, there were 276,667 options exercised on a cashless basis resulting in the issuance of 141,050 shares of common stock. The aggregate intrinsic value of the options exercised was $1,015,585. During the year ended August 31, 2017, there were 130,000 options exercised on a cashless basis resulting in the issuance of 46,520 shares of common stock. The aggregate intrinsic value of the options exercised was $186,500. On November 15, 2016, the Company granted 35,000 options to two employees with an exercise price of $3.28. On July 7, 2017, the Company finalized and executed two consulting agreements with third parties to provide business development services. The terms and conditions of each consulting agreement are similar and provide for combined compensation of $26,000 per month in cash and the grant of 1,500,000 common stock purchase options with an exercise price of $2.70 per share, and which vest upon the achievement of performance milestones and upon Board approval. The 1,500,000 stock options granted to consultants had a grant date fair value of $1.84 per option. As of February 28, 2018, the Company continues to address the conditions that would lead to the achievement of the performance milestones identified in the consulting agreements. Compensation expense will be recorded for the options when the performance milestones become probable of being achieved. The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Consolidated Statements of Operations for the three and six months ended February 28, 2018 and 2017: Three Months Ended Six Months Ended February 28, February 28, 2018 2017 2018 2017 Stock Compensation Expense: SG&A $ 181,201 $ 26,667 $ 580,676 $ 79,722 R&PD 178,980 11,695 293,778 57,240 Total $ 360,181 $ 38,362 $ 874,454 $ 136,962 As of February 28, 2018, the Company had $5,801,820 of unrecognized compensation cost related to unvested stock options. Of the unrecognized compensation expense, $3,041,820 is expected to be recognized over a period of 4.0 years and $2,760,000 of compensation expense will be recorded when and if the performance milestones, from the two consulting agreements described above, become probable of being achieved. The following table summarizes information about stock options outstanding and exercisable at February 28, 2018: Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price $ 2.70 1,500,000 4.36 2.70 - 4.36 2.70 3.28 17,500 8.72 3.28 17,500 8.72 3.28 3.46 35,000 7.85 3.46 25,000 7.85 3.46 4.87 217,500 9.73 4.87 97,500 9.73 4.87 5.35 1,008,000 9.85 5.35 42,000 9.85 5.35 5.94 33,334 2.82 5.94 33,334 2.82 5.94 Total 2,811,334 6.79 $ 3.87 215,334 8.38 $ 4.84	Stock option grants pursuant to the 2006 Plan vest either immediately or over one to five years and expire ten years after the date of grant. Stockholders previously approved 5,000,000 shares for grant under the 2006 Plan, of which 2,072,580 remain available for grant and 1,013,334 were issued pursuant to the exercise of vested options as of August 31, 2017. All shares approved for grant and subsequently forfeited are available for future grant. The Company does not repurchase shares to fulfill the requirements of options that are exercised. The Company issues new shares when options are exercised. The 2006 Plan was approved by stockholders on February 7, 2011 and expires according to its terms on February 7, 2021. The Company employs the following key weighted-average assumptions in determining the fair value of stock options, using the Black-Scholes option pricing model and the simplified method to estimate the expected term of “plain vanilla” options: Year Ended Year Ended August 31, 2017 August 31, 2016 Expected dividend yield – – Expected stock price volatility 79% - 81 % 82 % Risk-free interest rate 1.95% - 2.03 % 2.06 % Expected term (in years) 5.00 - 7.67 7.67 Exercise price $ 2.71 $ 3.46 Weighted-average grant date fair-value $ 1.85 $ 2.64 A summary of the Company’s stock option activity for the years ended August 31, 2017 and 2016 and related information follows: Number of Shares Subject to Option Grants Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at August 31, 2015 1,267,502 2.68 Grants 65,000 3.46 Forfeitures (55,834 ) 3.23 Exercises (556,667 ) 2.22 Outstanding at August 31, 2016 720,001 3.06 Grants 1,535,000 2.71 Exercises (130,000 ) 2.62 Outstanding at August 31, 2017 2,125,001 2.84 5.31 years 2,969,800 Exercisable at August 31, 2017 237,501 3.51 6.01 years 233,900 Available for grant at August 31, 2017 2,072,580 The aggregate intrinsic value in the table above represents the total pretax intrinsic value for all “in-the-money” options (i.e. the difference between the Company’s closing stock price on the last trading day of the period covered by this report and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all in-the-money option holders exercised their vested options on August 31, 2017. The intrinsic value of the option changes based upon the fair market value of the Company’s common stock. Since the closing stock price was $4.20 on August 31, 2017 and 2,075,000 outstanding options have an exercise price below $4.20 per share, as of August 31, 2017, there is intrinsic value to the Company’s outstanding, in-the-money stock options, including 187,500 options that are exercisable and in-the-money. During the year ended August 31, 2017, there were 130,000 options exercised on a cashless basis resulting in the issuance of 46,520 shares of common stock. The aggregate intrinsic value of the options exercised was $186,500. During the year ended August 31, 2016, there were 556,667 options exercised on a cashless basis resulting in the issuance of 282,106 shares of common stock. The aggregate intrinsic value of the options exercised during the year ended August 31, 2016 was $1,277,834. On November 15, 2016, the Company granted 35,000 options to two employees with an exercise price of $3.28. On July 7, 2017, the Company finalized and executed two consulting agreements with third parties to provide business development services. The terms and conditions of each consulting agreement are similar and provide for combined compensation of $26,000 per month in cash and the grant of 1,500,000 common stock purchase options with an exercise price of $2.70 per share, and which vest upon the achievement of performance conditions and upon Board approval. The 1,500,000 stock options granted to consultants had a grant date fair value of $1.84 per option. As of August 31, 2017, the Company determined the achievement of the performance conditions was not probable. Compensation expense will be recorded for the options with performance conditions when and if the performance conditions become probable of being achieved. The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Consolidated Statements of Operations for the years ended August 31, 2017 and 2016: Years Ended August 31, 2017 2016 Stock Compensation Expense: SG&A $ 118,969 $ 211,406 R&D 80,630 97,357 Total $ 199,599 $ 308,763 As of August 31, 2017, the Company had $2,792,847 of unrecognized compensation cost related to unvested stock options. Of the unrecognized compensation expense, $32,847 is expected to be recognized over a period of 1.25 years and $2,760,000 of compensation expense will be recorded when and if the performance conditions become probable of being achieved. The following table summarizes information about stock options outstanding and exercisable at August 31, 2017: Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price $ 0.80 5,000 5.31 $ 0.80 5,000 5.31 $ 0.80 1.40 5,000 7.30 1.40 5,000 7.30 1.40 2.50 10,000 3.60 2.50 10,000 3.60 2.50 2.70 1,500,000 5.00 2.70 - 5.00 2.70 2.90 455,000 6.41 2.90 105,000 6.41 2.90 3.28 35,000 9.21 3.28 17,500 9.21 3.28 3.46 65,000 8.35 3.46 45,000 8.35 3.46 4.98 16,667 0.52 4.98 16,667 0.52 4.98 5.94 33,334 3.32 5.94 33,334 3.32 5.94 Total 2,125,001 5.31 $ 2.84 237,501 6.01 $ 3.51

Net Loss Per Share

Net Loss Per Share	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Notes to Financial Statements
NOTE 8 - Net Loss Per Share	During the three and six months ended February 28, 2018 and 2017, the Company recorded a net loss. Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the three and six months ended February 28, 2018 and 2017: Three Months Ended February 28, Six Months Ended February 28, 2018 2017 2018 2017 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (1,489,463 ) $ (1,286,271 ) $ (4,188,615 ) $ (3,008,801 ) Denominator: Weighted average number of common shares outstanding 36,135,080 28,666,741 35,743,320 28,615,533 Basic and diluted EPS $ (0.04 ) $ (0.04 ) $ (0.12 ) $ (0.11 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 2,811,334 625,001 2,811,334 625,001 Warrants 2,909,850 11,586,631 2,909,850 11,586,631 Convertible debt 3,004,655 2,772,057 3,004,655 2,772,057 Warrants issuable upon conversion of debt (See "NOTE 2 - Debt" above) 3,004,655 2,772,057 3,004,655 2,772,057 Total shares not included in the computation of diluted losses per share 11,730,494 17,755,746 11,730,494 17,755,746	During the years ended August 31, 2017 and 2016, the Company recorded a net loss. Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the years ended August 31, 2017 and 2016: Years Ended August 31, 2017 2016 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (5,353,425 ) $ (4,637,313 ) Denominator: Weighted average number of common shares outstanding 31,299,979 27,295,540 Basic and diluted EPS $ (0.17 ) $ (0.17 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 2,125,001 720,001 Warrants 4,115,000 11,586,631 Convertible debt 2,870,739 2,678,280 Warrants issuable upon conversion of debt (See "NOTE 3 - Debt" above) 2,870,739 2,678,280 Total shares not included in the computation of diluted losses per share 11,981,479 17,663,192

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Notes to Financial Statements
NOTE 9 - Related Party Transactions	A related party with respect to the Company is generally defined as any person (i) (and, if a natural person, inclusive of his or her immediate family) that holds 10% or more of the Company’s securities, (ii) that is part of the Company’s management, (iii) that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. The law firm of Satterlee Stephens LLP (“Satterlee”), of which Joseph Sierchio, one of the Company’s directors, is a partner, provides counsel to the Company. Mr. Sierchio is the Company’s primary attorney. Fees billed by Satterlee during the three months ended February 28, 2018 and 2017, totaled $71,767 and $45,005, respectively, and $145,834 and $151,555 during the six months ended February 28, 2018 and 2017. At February 28, 2018 and August 31, 2017, the Company owed Satterlee $71,767 and $105,184, respectively, which is included in accounts payable. Mr. Sierchio continues to serve as a director of the Company. On August 7, 2017, the Company appointed Jatinder Bhogal to the Board of Directors. Mr. Bhogal has provided consulting services to the Company through his wholly owned company, Vector Asset Management, Inc., pursuant to a Consulting Agreement dated February 1, 2014 as amended on November 11, 2016. Pursuant to the Consulting Agreement, Mr. Bhogal receives compensation of $5,000 per month. In connection with the Consulting Agreement, during the three months ended February 28, 2018 and 2017, the Company recognized expense $15,000 and $15,000, respectively, and $30,000 and $30,000 of expense during the six months ended February 28, 2018 and 2017, respectively. On November 3, 2017, the Company entered into the Third Amendment to the 2013 Bridge Loan Agreement and the Third Amendment to the 2015 Bridge Loan Agreement with the Investor pursuant to which the Company and the Investor agreed to extend the maturity date to December 31, 2019. Pursuant to the Third Amendment to the 2013 Bridge Loan Agreement and the Third Amendment to the 2015 Bridge Loan Agreement, the rate of interest increased to 10.5% and the following warrants, held by the Investor, had their maturity date extended to December 31, 2022: a) Series M Warrant to purchase 246,000 shares; b) Series N Warrant to purchase 767,000 shares; c) Series P Warrant to purchase 213,500 shares; d) Series R Warrant to purchase 468,750; and e) Series S-A Warrant to purchase 300,000 shares. As a result of extending the expiration date of the above warrants to December 31, 2022, the Company recognized an additional debt discount to the 2013 Note of $1,074,265 as of November 3, 2017. For additional information related to our warrants, please see “NOTE 4 – Common Stock and Warrants”. For additional information related to our debt, please see “NOTE 2 – Debt”. All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.	A related party with respect to the Company is generally defined as any person (i) (and, if a natural person, inclusive of his or her immediate family) that holds 10% or more of the Company’s securities, (ii) that is part of the Company’s management, (iii) that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. The law firm of Sierchio & Partners, LLP, of which Joseph Sierchio, one of the Company’s directors, was a principal, had provided counsel to the Company since its inception. Beginning in September 2016, Mr. Sierchio became a partner at Satterlee Stephens LLP (“Satterlee”). Concurrently with Mr. Sierchio’s move to Satterlee, the Company engaged with Satterlee to provide legal counsel with Mr. Sierchio maintaining his role as the Company’s primary attorney. During the years ended August 31, 2017 and 2016, the Company recognized $321,739 and $291,951 of fees for legal services billed by firms associated with Mr. Sierchio. At August 31, 2017, the Company owed Satterlee $105,184 which is included in accounts payable. There are no accounts payable to Sierchio & Partners, LLP as of August 31, 2017. Mr. Sierchio continues to serve as a director of the Company. At August 31, 2016, the Company owed Sierchio & Partners, LLP $53,467 which is included in accounts payable. On August 7, 2017, the Company appointed Jatinder Bhogal to the Board of Directors. Mr. Bhogal has provided consulting services to the Company through his wholly owned company, Vector Asset Management, Inc., pursuant to a Consulting Agreement dated February 1, 2014 as amended on November 11, 2016. Pursuant to the Consulting Agreement, Mr. Bhogal received compensation of $5,000 per month. During each of the years ended August 31, 2017 and 2016, the Company recognized $60,000 of expense in connection with the Consulting Agreement. On July 24, 2017, the Company entered into the July 2017 Private Placement with the Investor for the sale of 300,000 units at a price of $2.30 per unit for $690,000 in aggregate proceeds. Each unit consisted of one share of common stock and one Series S-A Warrant to purchase one (1) share of common stock at an exercise price of $2.53 per share through July 24, 2022. The warrants may be exercised on a cashless basis. On March 2, 2017, the Investor exercised outstanding warrants to purchase up to 7,642,631 shares of the Company’s common stock on a cashless basis, consisting of: (i) a Series I Warrant to purchase up to 921,875 shares; (ii) a Series J Warrant to purchase up to 3,110,378 shares; (iii) a Series K Warrant to purchase up to 3,110,378 shares; and (iv) a Series L Warrant to purchase up to 500,000 shares, resulting in the issuance of 5,215,046 shares of common stock. On November 14, 2016, the Company paid the March 2015 Note in full resulting in a payment to the Investor totaling $19,599 representing $18,146 of principal and $1,453 of accrued interest. On October 7, 2013, the Company entered into the 2013 Loan Agreement with the Investor. On November 10, 2014, the Company and the Investor entered into the 2015 Loan Agreement resulting in the extension of the 2013 Note’s maturity date to December 31, 2015 and the issuance of a Series J Warrant to purchase 3,110,378 shares of our common stock and a Series K Warrant to purchase 3,110,378 shares of our common stock. On December 31, 2015, the Company entered into the 2015 Second Amended Loan Agreement with the Investor resulting in the extension of the 2013 Note’s maturity date to December 31, 2017 and the issuance of a Series N Warrant to purchase 767,000 shares of our common stock. Additionally, as consideration for the Investor agreeing to extend the 2013 Note maturity date to December 31, 2017, the Company extended the maturity date of the Series I Warrant to purchase 921,875 shares of common stock from October 6, 2018 to December 31, 2020, and extended the maturity date of the Series J Warrant to purchase 3,110,378 shares of common stock and Series K Warrant to purchase 3,110,378 shares of common stock from November 9, 2019 to December 31, 2020. For more information, see “NOTE 3 - Debt” above. On December 7, 2015, the Company entered into a Bridge Loan Agreement with the Investor pursuant to which the Company may borrow up to $550,000; of which $400,000 was advanced on October 7, 2015 and $150,000 on December 22, 2015 (each advance includes an additional $5 related to wire fees). As a condition to the Investor’s entry into the December 2015 Loan Agreement, the Company issued the Investor a Series M Stock Purchase Warrant to purchase up to 275,000 shares of the Company’s common stock for a period of five years, with an exercise price of $2.34. Additionally, as consideration for the Investor agreeing to extend the 2013 Note maturity date to December 31, 2017, the Company extended the maturity date of the Series M Warrant to purchase 275,000 shares of common stock from December 7, 2020 to December 31, 2020. For more information, see “NOTE 3 – Debt” above. During the year ended August 31, 2016, the Investor purchased 250 PPM Units related to the March 2016 Private Placement resulting in the Company receiving $775,000. Additionally, the Investor converted $548,700 of principal owed under the December 2015 Loan Agreement in exchange for 177 PPM units. As a result, the Company issued 427,000 shares of common stock, 427,000 Series O Warrants, and 213,500 Series P Warrants. For more information, see “NOTE 3 – Debt” and “NOTE 4 – Private Placement” above. During the year ended August 31, 2016, the Investor purchased 468,750 units under the June 2016 Private Placement resulting in the Company receiving $1,500,000 and issuing 468,750 shares of common stock, 468,750 Series Q Warrants, and 468,750 Series R Warrants. For more information, see “NOTE 4 – Private Placement” above. During the year ended August 31, 2016, the Company received and repaid a short term cash advance from the Investor totaling $25,720. All related party transactions are recorded at the exchange amount established and agreed to between related parties and are in the normal course of business.

Income Taxes

Income Taxes	12 Months Ended
	Aug. 31, 2017
Notes to Financial Statements
NOTE 10 - Income Taxes	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets at August 31, 2017 and 2016 are as follows: 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 7,120,032 $ 5,995,528 Capitalized research and development 1,431,748 1,285,254 Depreciation (7,137 ) (82 ) Stock based compensation 1,168,629 1,207,988 Foreign affiliate interest expense 296,315 190,173 Research and development credit carry forward 438,298 369,117 Total deferred tax assets 10,447,885 9,047,979 Less: valuation allowance (10,447,885 ) (9,047,979 ) Net deferred tax asset $ - $ - The net increase in the valuation allowance for deferred tax assets was $1,399,906 and $1,342,798 for the years ended August 31, 2017 and 2016, respectively. The Company evaluates its valuation allowance requirements on an annual basis based on projected future operations. When circumstances change and this causes a change in management’s judgment about the realizability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current operations. For federal income tax purposes, the Company has net U.S. operating loss carry forwards at August 31, 2017 available to offset future federal taxable income, if any, of $20,941,270, which will fully expire between the period from August 31, 2020 to August 31, 2037. Accordingly, there is no current tax expense for the years ended August 31, 2017 and 2016. In addition, the Company has research and development tax credit carry forwards of $438,298 at August 31, 2017, which are available to offset federal income taxes and begin to expire during the fiscal year ending August 31, 2027. The utilization of the tax net operating loss carry forwards may be limited due to ownership changes that have occurred as a result of sales of common stock. The effects of state income taxes were insignificant for the years ended August 31, 2017 and 2016. The following is a reconciliation between expected income tax benefit and actual, using the applicable statutory income tax rate of 34% for the years ended August 31, 2017 and 2016: 2017 2016 Income tax benefit at statutory rate $ 1,820,165 $ 1,576,686 Permanent differences (490,980 ) (297,211 ) Research and development credit 70,721 63,323 Change in valuation allowance (1,399,906 ) (1,342,798 ) $ - $ - The fiscal years 2015 through 2017 remain open to examination by federal authorities and other jurisdictions in which the Company operates.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Notes to Financial Statements
NOTE 11 - Subsequent Events	Management has reviewed material events subsequent of the period ended February 28, 2018 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”. On March 15, 2018 the Company received notification it has been awarded its first-ever advanced materials manufacturing Cooperative Research and Development Agreement (CRADA) from the U.S. Department of Energy (DOE) Office of Energy Efficiency and Renewable Energy’s (EERE) Advanced Manufacturing Office (AMO). On March 13, 2018 the company Board of Directors appointed Mr. Harmel S. Rayat, company founder and longtime majority stockholder, as Chairman of its Board of Directors. On March 3, 2018, a holder of our Series P Warrants exercised 500 warrants at an exercise price of $3.70 per share resulting in $1,850 to the Company and the issuance of 500 shares of common stock. On April 13, 2018, a holder of our Series P Warrants exercised 1,000 warrants at an exercise price of $3.70 per share resulting in $3,700 to the Company and the issuance of 500 shares of common stock. On April 13, 2018, an employee exercised 15,000 stock purchase options on a cashless basis resulting in the issuance of 5,112 shares of common stock.	Management has reviewed material events subsequent of the period ended August 31, 2016 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”. On September 7, 2017, John Conklin, the Company’s President & CEO, exercised 100,000 stock purchase options on a cashless basis resulting in the issuance of 46,097 shares of common stock. On September 7, 2017, two other employees exercised a total of 72,500 stock purchase options on a cashless basis resulting in the issuance of 33,151 shares of common stock. On September 7, 2017, the Investor exercised their outstanding Series Q Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 189,940 shares of common stock. On September 7, 2017, a third party exercised their outstanding Series Q Warrant to purchase up to 468,750 shares of the Company’s common stock on a cashless basis, resulting in the issuance of 189,940 shares of common stock. On September 11, 2017, the Company initiated and on September 29, 2017, completed a self-directed offering of 821,600 units at a price of $3.11 per unit for $2,555,176 in aggregate proceeds (the “ September 2017 Private Placement Subsequent to year end, holders of our Series O Warrants exercised 80,000 warrants at an exercise price of $3.10 per share resulting in $248,000 to the Company and the issuance of 80,000 shares of common stock. On November 3, 2017, the Company entered into the Third Amendment to the 2013 Bridge Loan Agreement with the Investor pursuant to which the Company and the Investor amended the 2013 Note to extend the maturity date to December 31, 2019. On November 3, 2017, the Company entered into the Third Amendment to the 2015 Bridge Loan Agreement with the Investor pursuant to which the Company and the Investor amended the March 2015 loan to extend the maturity date to December 31, 2019. Pursuant to the Third Amendment to the 2013 Bridge Loan Agreement and the Third Amendment to the 2015 Bridge Loan Agreement, the rate of interest increased to 10.5% and the following warrants, held by the Investor, had their maturity date extended to December 31, 2022: a) Series M Warrant to purchase 246,000 shares; b) Series N Warrant to purchase 767,000 shares; c) Series P Warrant to purchase 213,500 shares; d) Series R Warrant to purchase 468,750; and e) Series S-A Warrant to purchase 300,000 shares. For additional information related to our warrants, please see “NOTE 6 – Common Stock and Warrants”.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Summary Of Significant Accounting Policies Policies
Principles of Consolidation		Kinetic Energy Corporation (“KEC”) was incorporated on June 19, 2008, in the State of Nevada and holds the patents related to the Company’s MotionPower™ technology. The Company’s business activities related to the MotionPower™ technology are conducted through KEC. New Energy Solar was incorporated on February 9, 2009, in the State of Florida and entered into agreements with The University of South Florida Research Foundation (“USF”) to sponsor research related to the Company’s SolarWindow™ technology. On February 18, 2015, the Company terminated the license agreement entered into with USF which originated on June 21, 2010. These consolidated financial statements presented are those of the Company and its wholly owned subsidiaries, KEC, and New Energy Solar. All significant intercompany balances and transactions have been eliminated.
Estimates		The preparation of the Company’s consolidated financial statements requires management to make estimates and use assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. On an on-going basis, the Company evaluates its estimates. Actual results and outcomes may differ materially from these estimates and assumptions.
Cash and Cash Equivalents		Cash and cash equivalents includes highly liquid investments with original maturities of three months or less. The Company has amounts deposited with financial institutions in excess of federally insured limits.
Property, Plant, and Equipment		Fixed assets are carried at cost, less accumulated depreciation and amortization. Major improvements are capitalized, while repair and maintenance are expensed when incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. Depreciation is computed on a straight-line basis over estimated useful lives of the related assets. The estimated useful lives of depreciable assets are: Estimated Useful Lives Office equipment 3-5 years Furniture & equipment 5 - 7 years
Fair Value Measurement		The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 1 inputs. Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 2 inputs. Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities measured and recorded on a recurring or nonrecurring basis with Level 3 inputs.
Fair Value of Financial Instruments		The carrying value of cash and cash equivalents, accounts payable and interest payable approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of the Company’s notes payable due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.
Research and Development		Research and development costs represent costs incurred to develop the Company’s technology, including salaries and benefits for research and development personnel, allocated overhead and facility occupancy costs, supplies, equipment purchase and repair and other costs. Research and development costs are expensed when incurred, except for nonrefundable advance payments for future research and development activities which are capitalized and recognized as expense as the related services are performed.
Stock-Based Compensation		The Company measures all employee stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company has granted stock options with performance conditions to certain nonemployee consultants. At each reporting date, the Company evaluates whether the achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon the assessment of achievement of each performance condition or the occurrence of the event which will trigger the options to vest. The Company uses the Black-Scholes-Merton formula to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes-Merton formula requires management to make assumptions regarding the option lives, expected volatility, and risk free interest rates. See “NOTE 6 – Common Stock and Warrants” and “NOTE 7 - Stock Options” for additional information on the Company’s stock-based compensation plans.
Income Taxes		The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.
Segment Reporting		The Company’s business is considered to be operating in one segment based upon the Company’s organizational structure, the way in which the operations are managed and evaluated, the availability of separate financial results and materiality considerations.
Net Income (Loss) Per Share		The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The computation of diluted net income per share does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on earnings per share. Therefore, when calculating EPS if the Company experienced a loss, there is no inclusion of dilutive securities as their inclusion in the EPS calculation is antidilutive. Furthermore, options and warrants will have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options or warrants (they are in the money). See “NOTE 8 - Net Loss Per Share” for further discussion.
Recent Accounting Pronouncements	In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. Management is currently assessing the impact the adoption of ASU 2017-09 will have on the Company’s Consolidated Financial Statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)”, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance is effective for our current fiscal year. The adoption of ASU 2016-09 did not have a material impact on the consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for our current fiscal year. The adoption of ASU 2015-17 did not have a material impact on the consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.	In March 2016, the Financial Accounting Standards Board (“ FASB ASU In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. The Company has determined that the adoption of ASU 2015-17 will currently have no impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.

Basis of Presentation, Organiza

Basis of Presentation, Organization, Recent Accounting Pronouncements and Going Concern (Policies)	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Basis Of Presentation Organization Recent Accounting Pronouncements And Going Concern Policies
Basis of Presentation	The unaudited financial statements of SolarWindow Technologies, Inc. (the “ Company GAAP KEC New Energy Solar
Organization	SolarWindow Technologies, Inc. was incorporated in the State of Nevada on May 5, 1998, under the name “Octillion Corp.” On December 2, 2008, the Company amended its Articles of Incorporation to effect a change of name to New Energy Technologies, Inc. Effective as of March 9, 2015, the Company amended its Articles of Incorporation to change its name to SolarWindow Technologies, Inc. to align the company name with its brand identity. The Company’s ticker symbol changed to WNDW. The Company has been developing two sustainable electricity generating systems. These novel technologies are branded as SolarWindow™ and MotionPower™. On March 2, 2015, the Company announced its exclusive focus on SolarWindow™. The Company’s SolarWindow™ technology harvests light energy from the sun and artificial sources to generate electricity from a transparent coating of organic photovoltaic solar cells applied to glass or plastics, creating a “photovoltaic” effect. Photovoltaics are best known as “solar panels” providing a method to generate electricity using solar cells to convert energy from the sun into a flow of electrons. Conventional PV power is generated by solar modules composed of interconnected mono- or poly-crystalline cells containing PV and electricity-conducting materials. These materials are usually opaque (i.e., not see-through) and only effectively generate electricity with sun light. The Company’s researchers have replaced these materials with a very thin layer of specially developed compounds that allow our SolarWindow™ technology to remain see-through or “transparent,” while generating electricity when exposed to either sun or artificial light. The Company’s SolarWindow™ research and product development programs involve ongoing efforts, and the commitment of significant resources to support the extensive invention, design, engineering, testing, prototyping, and intellectual property initiatives carried-out by its contract engineers, scientists, and consultants. The Company’s activities are subject to significant risks and uncertainties, including, but not limited to, the Company’s failure to secure, on a timely basis, adequate additional funding to commercialize its SolarWindow™ technology or the development of a similar technology and products, by existing or potential future competitors, who may gain earlier market entry or greater market acceptance than the Company’s technology and products.
Recent Accounting Pronouncements	In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. Management is currently assessing the impact the adoption of ASU 2017-09 will have on the Company’s Consolidated Financial Statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)”, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance is effective for our current fiscal year. The adoption of ASU 2016-09 did not have a material impact on the consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for our current fiscal year. The adoption of ASU 2015-17 did not have a material impact on the consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.	In March 2016, the Financial Accounting Standards Board (“ FASB ASU In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC 842, Leases. The new guidance requires the recognition of lease assets and liabilities for operating leases with terms of more than 12 months. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows will be generally consistent with the current lease accounting guidance. The ASU is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. The Company has determined that the adoption of ASU 2015-17 will currently have no impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017. The Company does not expect this accounting update to have a material effect on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.
Going Concern	The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. Due to the “start-up” nature of our business, we expect to incur losses as we continue development of our products and technologies. As of February 28, 2018, the Company has incurred recurring operating losses since inception of $43,218,367. As of February 28, 2018, the Company had approximately $1,841,672 of cash on hand and current liabilities of $148,296. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business. As of the date of filing of the Company’s most recent Form 10-K on November 22, 2017, based on management’s assessment, the Company had sufficient cash to meet its funding requirements for the next twelve months. However, currently, based upon the Company’s near term anticipated level of operations and expenditures, management believes that cash on hand should be sufficient to enable the Company to continue operations through November 2018 or approximately seven months from the date of this quarterly report. In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements. The Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company expects to seek additional funding through private equity or convertible debt. If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company’s business, operating results, financial condition and prospects. In particular, the Company may be required to delay; reduce the scope of or terminate its research and development programs; sell rights to its SolarWindow™ technology and/or MotionPower™ technology, or other technologies or products based upon these technologies; or license the rights to these technologies or products on terms that are less favorable to the Company than might otherwise be available.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Aug. 31, 2017
Summary Of Significant Accounting Policies Tables
Estimated useful lives	Estimated Useful Lives Office equipment 3-5 years Furniture & equipment 5 - 7 years

Debt (Tables)

Debt (Tables)	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Debt Tables
Principal maturities for notes payable		2018 - 2019 - 2020 3,600,000 Total $ 3,600,000
Outstanding debt	Issue Maturity Debt Interest Date Date Principal Discount Balance Payable As of February 28, 2018: March 2015 Loan as amended 3/4/2015 12/31/2019 $ 600,000 $ - $ 600,000 $ 146,747 2013 Note as amended 10/7/2013 12/31/2019 3,000,000 (914,762 ) 2,085,238 1,116,377 $ 3,600,000 $ (914,762 ) $ 2,685,238 $ 1,263,124 As of August 31, 2017: March 2015 Loan as amended 3/4/2015 12/31/2017 $ 600,000 $ - $ 600,000 $ 113,465 2013 Note as amended 10/7/2013 12/31/2017 3,000,000 (413,377 ) 2,586,623 932,912 $ 3,600,000 $ (413,377 ) $ 3,186,623 $ 1,046,377

Derivative Liability Related 22

Derivative Liability Related to the PPM Units (Tables)	12 Months Ended
	Aug. 31, 2017
Derivative Liability Related To Ppm Units Tables
Summary of quantitative information derivative liability	Common stock issuable upon exercise of Series O Warrants 618,000 Common stock issuable upon exercise of Series P Warrants 309,000 Stock price $3.13 - $4.19 Volatility (Annual) 80% - 83% Strike price $3.10, Series O Warrants; $3.70, Series P Warrants Risk-free rate 0.71% - 0.80% Series O Warrants; 0.71% - 0.79%, Series P Warrants Term 1.4 – 1.7 years Series O Warrants; 2.1 - 2.2 years, Series P Warrants Probability of Reset Adjustment 0% - 100%
Fair value of derivative liabilities	Balance at August 31, 2015 Initial valuation of derivative liabilities upon issuance of new securities during the period Increase (decrease) in fair value of derivative liabilities Balance at August 31, 2016 Warrant liability $ - $ 1,714,395 $ (1,714,395 ) $ -

Common Stock and Warrants (Tabl

Common Stock and Warrants (Tables)	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Common Stock And Warrants Tables
Warrants outstanding and exercisable	Shares of Common Stock Issuable from Warrants Outstanding as of Weighted Average February 28, August 31, Exercise Description 2018 2017 Price Expiration Series M 246,000 246,000 $ 2.34 December 31, 2022 Series N 767,000 767,000 $ 3.38 December 31, 2022 Series O - 618,000 $ 3.10 October 31, 2017 Series P 306,500 309,000 $ 3.70 April 30, 2018 Series Q - 937,500 $ 3.20 December 31, 2022 Series R 468,750 937,500 $ 4.00 December 31, 2022 Series S-A 300,000 300,000 $ 2.53 December 31, 2022 Series S 821,600 - $ 3.42 September 29, 2022 Total 2,909,850 4,115,000	Shares of Common Stock Issuable from Warrants Outstanding as of Weighted Average August 31, August 31, Exercise Description 2017 2016 Price Expiration Series I - 921,875 $ 1.37 December 31, 2020 Series J - 3,110,378 $ 1.12 December 31, 2020 Series K - 3,110,378 $ 1.20 December 31, 2020 Series L - 500,000 $ 1.20 December 7, 2020 Series M 246,000 375,000 $ 2.34 December 31, 2020 Series N 767,000 767,000 $ 3.38 December 31, 2020 Series O 618,000 618,000 $ 3.10 October 31, 2017 Series P 309,000 309,000 $ 3.70 April 30, 2018 Series Q 937,500 937,500 $ 3.20 June 20, 2019 Series R 937,500 937,500 $ 4.00 June 20, 2021 Series S-A 300,000 - $ 2.53 July 24, 2022 Total 4,115,000 11,586,631

Stock Options (Tables)

Stock Options (Tables)	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Stock Options Tables
Fair value of each option award	Six Months Ended February 28, 2018 2017 Expected dividend yield – – Expected stock price volatility 83.43% – 83.55% 79% - 81% Risk-free interest rate 2.27% - 2.33% 1.95% - 2.03% Expected term (in years) 7.67 5.00 - 7.67 Exercise price $4.87 - $5.35 $ 2.71 Weighted-average grant date fair-value $3.76 - $5.64 $ 1.85	Year Ended Year Ended August 31, 2017 August 31, 2016 Expected dividend yield – – Expected stock price volatility 79% - 81 % 82 % Risk-free interest rate 1.95% - 2.03 % 2.06 % Expected term (in years) 5.00 - 7.67 7.67 Exercise price $ 2.71 $ 3.46 Weighted-average grant date fair-value $ 1.85 $ 2.64
Stock option activity	Number of Shares Subject to Option Grants Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at August 31, 2016 720,001 3.06 Grants 1,535,000 2.71 Exercises (130,000 ) 2.62 Outstanding at August 31, 2017 2,125,001 2.84 Grants 1,263,000 5.25 Forfeitures (300,000 ) 2.90 Exercises (276,667 ) 3.30 Outstanding at February 28, 2018 2,811,334 3.87 6.79 years 5,154,075 Exercisable at February 28, 2018 215,334 4.84 8.38 years 193,975	Number of Shares Subject to Option Grants Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at August 31, 2015 1,267,502 2.68 Grants 65,000 3.46 Forfeitures (55,834 ) 3.23 Exercises (556,667 ) 2.22 Outstanding at August 31, 2016 720,001 3.06 Grants 1,535,000 2.71 Exercises (130,000 ) 2.62 Outstanding at August 31, 2017 2,125,001 2.84 5.31 years 2,969,800 Exercisable at August 31, 2017 237,501 3.51 6.01 years 233,900 Available for grant at August 31, 2017 2,072,580
Share-based compensation cost	Three Months Ended Six Months Ended February 28, February 28, 2018 2017 2018 2017 Stock Compensation Expense: SG&A $ 181,201 $ 26,667 $ 580,676 $ 79,722 R&PD 178,980 11,695 293,778 57,240 Total $ 360,181 $ 38,362 $ 874,454 $ 136,962	Years Ended August 31, 2017 2016 Stock Compensation Expense: SG&A $ 118,969 $ 211,406 R&D 80,630 97,357 Total $ 199,599 $ 308,763
Stock options outstanding and exercisable	Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price $ 2.70 1,500,000 4.36 2.70 - 4.36 2.70 3.28 17,500 8.72 3.28 17,500 8.72 3.28 3.46 35,000 7.85 3.46 25,000 7.85 3.46 4.87 217,500 9.73 4.87 97,500 9.73 4.87 5.35 1,008,000 9.85 5.35 42,000 9.85 5.35 5.94 33,334 2.82 5.94 33,334 2.82 5.94 Total 2,811,334 6.79 $ 3.87 215,334 8.38 $ 4.84	Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price $ 0.80 5,000 5.31 $ 0.80 5,000 5.31 $ 0.80 1.40 5,000 7.30 1.40 5,000 7.30 1.40 2.50 10,000 3.60 2.50 10,000 3.60 2.50 2.70 1,500,000 5.00 2.70 - 5.00 2.70 2.90 455,000 6.41 2.90 105,000 6.41 2.90 3.28 35,000 9.21 3.28 17,500 9.21 3.28 3.46 65,000 8.35 3.46 45,000 8.35 3.46 4.98 16,667 0.52 4.98 16,667 0.52 4.98 5.94 33,334 3.32 5.94 33,334 3.32 5.94 Total 2,125,001 5.31 $ 2.84 237,501 6.01 $ 3.51

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Net Loss Per Share Tables
Computation of basic and diluted net loss per share	Three Months Ended February 28, Six Months Ended February 28, 2018 2017 2018 2017 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (1,489,463 ) $ (1,286,271 ) $ (4,188,615 ) $ (3,008,801 ) Denominator: Weighted average number of common shares outstanding 36,135,080 28,666,741 35,743,320 28,615,533 Basic and diluted EPS $ (0.04 ) $ (0.04 ) $ (0.12 ) $ (0.11 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 2,811,334 625,001 2,811,334 625,001 Warrants 2,909,850 11,586,631 2,909,850 11,586,631 Convertible debt 3,004,655 2,772,057 3,004,655 2,772,057 Warrants issuable upon conversion of debt (See "NOTE 2 - Debt" above) 3,004,655 2,772,057 3,004,655 2,772,057 Total shares not included in the computation of diluted losses per share 11,730,494 17,755,746 11,730,494 17,755,746	Years Ended August 31, 2017 2016 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (5,353,425 ) $ (4,637,313 ) Denominator: Weighted average number of common shares outstanding 31,299,979 27,295,540 Basic and diluted EPS $ (0.17 ) $ (0.17 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 2,125,001 720,001 Warrants 4,115,000 11,586,631 Convertible debt 2,870,739 2,678,280 Warrants issuable upon conversion of debt (See "NOTE 3 - Debt" above) 2,870,739 2,678,280 Total shares not included in the computation of diluted losses per share 11,981,479 17,663,192

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Aug. 31, 2017
Income Taxes Tables
Deferred income taxes	2017 2016 Deferred tax assets: Net operating loss carryforwards $ 7,120,032 $ 5,995,528 Capitalized research and development 1,431,748 1,285,254 Depreciation (7,137 ) (82 ) Stock based compensation 1,168,629 1,207,988 Foreign affiliate interest expense 296,315 190,173 Research and development credit carry forward 438,298 369,117 Total deferred tax assets 10,447,885 9,047,979 Less: valuation allowance (10,447,885 ) (9,047,979 ) Net deferred tax asset $ - $ -
Reconciliation income tax benefit	2017 2016 Income tax benefit at statutory rate $ 1,820,165 $ 1,576,686 Permanent differences (490,980 ) (297,211 ) Research and development credit 70,721 63,323 Change in valuation allowance (1,399,906 ) (1,342,798 ) $ - $ -

Organization and Going Concern

Organization and Going Concern (Details Narrative) - USD ($)	Nov. 03, 2017	Sep. 29, 2017	Oct. 31, 2017	Feb. 28, 2018	Aug. 31, 2017	Aug. 31, 2016
State of incorporation				State of Nevada	State of Nevada
Date of incorporation				May 5, 1998	May 5, 1998
Cash				$ 1,841,672	$ 670,853	$ 2,509,215
Retained deficit				(43,218,367)	(39,029,752)	(33,676,327)
Total current liabilities				$ 148,296	$ 230,184	$ 794,588
Investor [Member] | 2013 Bridge Loan Agreement [Member]
Maturity date	Dec. 31, 2019
Investor [Member] | 2015 Bridge Loan Agreement [Member]
Maturity date	Dec. 31, 2019
Subsequent Event [Member] | Series O Warrants [Member]
Proceeds from sale of common stock and warrants			$ 248,000
Warrants exercise			80,000
Subsequent Event [Member] | Investor [Member] | 2013 Bridge Loan Agreement [Member]
Principal amount	$ 3,000,000
Maturity date	Dec. 31, 2019
Subsequent Event [Member] | Investor [Member] | 2015 Bridge Loan Agreement [Member]
Principal amount	$ 600,000
Maturity date	Dec. 31, 2019
Subsequent Event [Member] | Private Placement [Member] | Investor [Member]
Proceeds from sale of common stock and warrants		$ 2,555,176

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Aug. 31, 2017
Office Equipment [Member] | Minimum [Member]
Estimated useful lives	3 years
Office Equipment [Member] | Maximum [Member]
Estimated useful lives	5 years
Furniture & equipment [Member] | Minimum [Member]
Estimated useful lives	5 years
Furniture & equipment [Member] | Maximum [Member]
Estimated useful lives	7 years

Debt (Details)

Debt (Details)	Aug. 31, 2017USD ($)
Debt Details
2,018
2,019
2,020	3,600,000
Total	$ 3,600,000

Debt (Details 1)

Debt (Details 1) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017
Principal	$ 3,600,000	$ 3,600,000
Debt Discount	(914,762)	(413,377)
Outstanding debt balances	2,685,238	3,186,623
Interest Payable	$ 1,263,124	$ 1,046,377
March 2015 Loan as amended [Member]
Issue Date	Mar. 4, 2015	Mar. 4, 2015
Maturity Date	Dec. 31, 2019	Dec. 31, 2017
Principal	$ 600,000	$ 600,000
Debt Discount
Outstanding debt balances	600,000	600,000
Interest Payable	$ 146,747	$ 113,465
2013 Note as amended [Member]
Issue Date	Oct. 7, 2013	Oct. 7, 2013
Maturity Date	Dec. 31, 2019	Dec. 31, 2017
Principal	$ 3,000,000	$ 3,000,000
Debt Discount	(914,762)	(413,377)
Outstanding debt balances	2,085,238	2,586,623
Interest Payable	$ 1,116,377	$ 932,912

Debt (Details Narrative)

Debt (Details Narrative)	Nov. 03, 2017USD ($)shares	Nov. 03, 2017USD ($)shares	Dec. 07, 2015USD ($)$ / sharesshares	Mar. 04, 2015USD ($)$ / sharesshares	Nov. 10, 2014USD ($)	Oct. 07, 2013USD ($)$ / sharesshares	Mar. 31, 2016USD ($)pure / Integershares	Dec. 31, 2015USD ($)$ / sharesshares	Feb. 28, 2018USD ($)shares	Feb. 28, 2017USD ($)	Mar. 31, 2016USD ($)pure / Integershares	Feb. 28, 2018USD ($)shares	Feb. 28, 2017USD ($)	Aug. 31, 2017USD ($)$ / sharesshares	Aug. 31, 2016USD ($)	Dec. 31, 2017shares	Mar. 02, 2017shares	Oct. 07, 2015shares
Debt discount attributable to the relative fair value					$ 3,629,309
Face value of note					$ 3,000,000
Accretion of debt discount									$ (227,733)	$ (323,932)		$ (572,880)	$ (687,991)	$ (1,311,445)	$ (2,335,954)
Interest expense									122,731	76,127		216,747	152,465	312,185	308,983
Additional debt discount								$ 2,476,875	$ 914,762			$ 914,762		413,377	1,650,120
Third Amendment to 2013 Bridge Loan Agreement [Member]
Maturity date	Dec. 31, 2022
Additional debt discount	$ 1,074,265	$ 1,074,265
Interest rate increase	10.50%
Third Amendment to 2013 Bridge Loan Agreement [Member] | Investor [Member]
Maturity date		Dec. 31, 2019
Additional debt discount	$ 1,074,265	$ 1,074,265
Interest rate increase		10.50%
2013 Bridge Loan Agreement [Member] | Investor [Member]
Maturity date	Dec. 31, 2019
2015 Bridge Loan Agreement [Member] | Investor [Member]
Maturity date	Dec. 31, 2019
Interest rate increase	10.50%
Subsequent Event [Member] | Third Amendment to 2013 Bridge Loan Agreement [Member]
Maturity date	Dec. 31, 2022
Interest rate increase	10.50%
Subsequent Event [Member] | Third Amendment 2015 Bridge Loan Agreement [Member]
Maturity date	Dec. 31, 2022
Interest rate increase	10.50%
Subsequent Event [Member] | 2013 Bridge Loan Agreement [Member] | Investor [Member]
Maturity date	Dec. 31, 2019
Subsequent Event [Member] | 2015 Bridge Loan Agreement [Member] | Investor [Member]
Maturity date	Dec. 31, 2019
Series J Warrant Member
Commom stock purchase | shares								3,110,378
Commom stock purchase price | $ / shares								$ 1.12
Exercisable date								Nov. 9, 2019
Series K Warrant Member
Commom stock purchase | shares								3,110,378
Commom stock purchase price | $ / shares								$ 1.20
Exercisable date								Nov. 9, 2019
Series I Warrant Member
Commom stock purchase | shares						921,875
Commom stock purchase price | $ / shares						$ 1.37
Convertible Promissory Note [Member]
Cash receved						$ 3,000,000
Promissory note annual interest rate			10.00%			7.00%
Maturity date			Sep. 1, 2016
Common stock conversion price			common stock at a conversion price equal to 85% of the thirty day volume weighted average price of the Company’s common stock
Debt instrument convertible beneficial conversion feature						The Investor may elect to convert principal and accrued interest into units of the Company's equity securities, with each Unit consisting of (a) one share of common stock; and (b) one Stock Purchase Warrant for the purchase of one share of common stock. The conversion price for each Unit is the lesser of (i) $1.37; or (ii) 70% of the 20 day average closing price of the Company's common stock prior to conversion, subject to a floor of $1.00 with the exercise price of each Warrant being equal to 60% of the 20 day average closing price of the Company's common stock prior to conversion. If issued, the Warrant included in the Units will be exercisable for a period of five years
Convertible Promissory Note [Member] | Warrant [Member]
Commom stock purchase | shares									3,004,655			3,004,655
Series L Warrant Member
Commom stock purchase | shares				500,000
Commom stock purchase price | $ / shares				$ 1.20
Debt discount attributable to the relative fair value														299,750
Accretion of debt discount														74,702	170,614
Additional debt discount				$ 33,000
Series M Warrant Member
Commom stock purchase | shares			275,000
Commom stock purchase price | $ / shares			$ 2.34
Accretion of debt discount														74,702	170,614
Bridge Loan One [Member]
Cash receved				$ 600,000
Promissory note annual interest rate				7.00%
Accretion of debt discount									$ 0	18,982		$ 0	74,702
Interest expense									$ (18,846)	(11,690)		$ (33,282)	(23,306)	47,832	44,742
Default rate				15.00%
Series M Stock Member
Commom stock purchase | shares			100,000
Commom stock purchase price | $ / shares			$ 2.34
Additional debt discount			$ 205,800
Bridge Loan [Member]
Cash receved			550,010
Wire fees			$ 10
Accretion of debt discount														0	458,777
Debt instrument convertible beneficial conversion feature							458,777
Interest expense														$ 695	17,604
PPM Member
Promissory note annual interest rate											10.00%
Commom stock purchase | shares							529,230				529,230
Investor received PPM Units							177				177
Coverted amount							$ 548,700				$ 548,700
Remaining amount							18,146				18,146
Inducement expense							$ 36,176				$ 36,176
Investor [Member]
Common stock conversion price					The conversion price for each Unit is the lesser of (i) $1.37; or (ii) 70% of the 20 day average closing price of the Company's common stock prior to conversion, subject to a floor of $1.00 with the exercise price of each Warrant being equal to 60% of the 20 day average closing price of the Company's common stock prior to conversion. If issued, the Warrant included in the Units will be exercisable for a period of five years.
Series J [Member]
Commom stock purchase | shares																	3,110,378
Series K [Member]
Commom stock purchase | shares																	3,110,378
Series I [Member]
Commom stock purchase | shares																	921,875
Series M [Member]
Commom stock purchase | shares														100,000
Series M [Member] | Investor [Member]
Commom stock purchase | shares																		275,000
December 31 2020 Member | Series J [Member]
Commom stock purchase | shares								3,110,378						3,110,378
Additional debt discount														$ 304,817
December 31 2020 Member | Series K [Member]
Commom stock purchase | shares								3,110,378						3,110,378		3,110,378
Additional debt discount														$ 326,590
December 31 2020 Member | Series I [Member]
Commom stock purchase | shares								921,875						921,875		3,110,378
Additional debt discount														$ 233,234
December 31 2020 Member | Series N [Member]
Commom stock purchase | shares								767,000						767,000
Commom stock purchase price | $ / shares														$ 3.38
Fair value of the Series N Warrant, per share | $ / shares														$ 2.102
Fair value of the Series N Warrant total														$ 1,612,234
December 31 2020 Member | Series M [Member] | Investor [Member]
Commom stock purchase | shares																		275,000
December 31 2022 Member | Series N [Member]
Maturity date												Dec. 31, 2020
Commom stock purchase | shares	767,000	767,000							767,000			767,000
Additional debt discount									$ 327,509			$ 327,509
Extended maturity date												Dec. 31, 2022
December 31 2022 Member | Series S [Member]
Maturity date												Jul. 24, 2022
Commom stock purchase | shares									300,000			300,000
Additional debt discount									$ 20,100			$ 20,100
Extended maturity date												Dec. 31, 2022
December 31 2022 Member | Series R [Member]
Maturity date												Jun. 20, 2021
Commom stock purchase | shares	468,750	468,750							468,750			468,750
Additional debt discount									$ 295,781			$ 295,781
Extended maturity date												Dec. 31, 2022
December 31 2022 Member | Series P [Member]
Maturity date												Apr. 30, 2018
Commom stock purchase | shares	213,500	213,500							213,500			213,500
Additional debt discount									$ 348,219			$ 348,219
Extended maturity date												Dec. 31, 2022
December 31 2022 Member | Series M [Member]
Maturity date												Dec. 31, 2020
Commom stock purchase | shares	246,000	246,000							246,000			246,000
Additional debt discount									$ 82,656			$ 82,656
Extended maturity date												Dec. 31, 2022
2013 Loan Agreement Member
Accretion of debt discount									227,733	304,950		$ 572,880	613,289	1,236,743	1,706,563
Interest expense									$ (103,885)	$ (64,437)		(183,465)	$ (128,473)	263,668	$ 246,637
Remaining debt discount												$ 914,762		$ 413,377

Private Placements (Details Nar

Private Placements (Details Narrative) - USD ($)	Sep. 11, 2017	Jul. 24, 2017	Jun. 20, 2016	Mar. 31, 2016	Sep. 29, 2017	Aug. 31, 2016
Number of PPM units exchange for cash						441
June 2016 Private Placement [Member]
Self directed shares issued			937,500
Self directed shares issued, per share			$ 3.20
Self directed shares issued, amount			$ 3,000,000
Exercise price of series Q stock			$ 3.20
Maturity date of series Q stock			Jun. 20, 2019
Exercise price of series R stock purchase warrant			$ 4
Maturity date of series R stock			Jun. 20, 2021
Relative fair value of common stock			$ 1,338,000
Relative fair value of series Q warrants			783,000
Relative fair value of series R warrants			$ 879,000
March 2016 Private Placement [Member]
Price per PPM unit of series O stock				$ 3.10
Net PPM unit price amount				$ 3,100
Exercise price of series P stock				$ 3.70
Maturity date of series P stock				Apr. 30, 2018
Number of PPM units issued				618
Number of PPM units exchange for cash				441
Proceeds from units in exchange for cash				$ 1,367,100
Conversion of units under loan agreement				177
Proceeds from conversion of principal owed				$ 548,700
Reset Price				$ 3.10
Expiration of reset adjustment				Sep. 30, 2016
July 2017 Private Placement [Member]
Self directed shares issued		300,000
Self directed shares issued, per share		$ 2.30
Self directed shares issued, amount		$ 690,000
Exercise price of series Q stock		$ 2.53
Relative fair value of common stock		$ 414,000
Relative fair value of series S-A warrants		$ 276,000
Market price per share		$ 3.20
Estimated volatility rate		76.13%
Risk free interest rate		1.83%
Expected dividend rate		0.00%
Expected life		5 years
September 2017 Private Placement [Member]
Self directed shares issued	821,600				821,600
Self directed shares issued, per share	$ 3.11				$ 3.11
Self directed shares issued, amount	$ 2,555,176				$ 2,555,176
Exercise price of series Q stock	$ 3.42
Relative fair value of common stock	$ 1,540,000
Relative fair value of series S-A warrants	$ 1,015,000
Market price per share	$ 3.95
Estimated volatility rate	77.96%
Risk free interest rate	1.71%
Expected dividend rate	0.00%
Expected life	5 years
Unit price, description	The unit price was based on a 15% discount to the average of the 30 day closing price (last day being Friday September 8, 2017) of the Company's common stock as reported on the OTCQB
Description of units issued	Each unit consisted of one share of common stock and one Series S Stock Purchase Warrant to purchase one (1) share of common stock at an exercise price of $3.42 per share through September 29, 2022

Derivative Liability Related 33

Derivative Liability Related to the PPM Units (Details)	12 Months Ended
	Aug. 31, 2016$ / sharesshares
Common stock issuable upon exercise of Series O Warrants | shares	618,000
Common stock issuable upon exercise of Series P Warrants | shares	309,000
Minimum [Member]
Stock price	$ 3.13
Volatility (Annual)	80.00%
Probability of Reset Adjustment	0.00%
Maximum [Member]
Stock price	$ 4.19
Volatility (Annual)	83.00%
Probability of Reset Adjustment	100.00%
Series O Warrants [Member]
Strike price	$ 3.10
Series O Warrants [Member] | Minimum [Member]
Risk-free rate	0.71%
Term	1 year 4 months 24 days
Series O Warrants [Member] | Maximum [Member]
Risk-free rate	0.80%
Term	1 year 8 months 12 days
Series P Warrants [Member]
Strike price	$ 3.70
Series P Warrants [Member] | Minimum [Member]
Risk-free rate	0.71%
Term	2 years 1 month 6 days
Series P Warrants [Member] | Maximum [Member]
Risk-free rate	0.79%
Term	2 years 2 months 12 days

Derivative Liability Related 34

Derivative Liability Related to the PPM Units (Details 1)	12 Months Ended
	Aug. 31, 2016USD ($)
Derivative Liability Related To Ppm Units Details 1
Beginning balance, warrant liability
Initial valuation of derivative liabilities upon issuance of new securities during the period	1,714,395
Increase (decrease) in fair value of derivative liabilities	(1,714,395)
Ending balance, warrant liability

Common Stock and Warrants (Deta

Common Stock and Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2016	Aug. 31, 2017	Aug. 31, 2015
Shares of Common Stock Issuable from Warrants	2,909,850	11,586,631	4,115,000
Weighted Average Exercise Price	$ 3.87	$ 3.06	$ 2.84	$ 2.68
Series I [Member]
Shares of Common Stock Issuable from Warrants		921,875
Weighted Average Exercise Price		$ 1.37
Expiration		Dec. 31, 2020
Series J [Member]
Shares of Common Stock Issuable from Warrants		3,110,378
Weighted Average Exercise Price		$ 1.12
Expiration		Dec. 31, 2020
Series K [Member]
Shares of Common Stock Issuable from Warrants		3,110,378
Weighted Average Exercise Price		$ 1.20
Expiration		Dec. 31, 2020
Series L [Member]
Shares of Common Stock Issuable from Warrants		500,000
Weighted Average Exercise Price		$ 1.20
Expiration		Dec. 7, 2020
Series M [Member]
Shares of Common Stock Issuable from Warrants	246,000	375,000	246,000
Weighted Average Exercise Price	$ 2.34	$ 2.34	$ 2.34
Expiration	Dec. 31, 2022	Dec. 31, 2020
Series N [Member]
Shares of Common Stock Issuable from Warrants	767,000	767,000	767,000
Weighted Average Exercise Price	$ 3.38	$ 3.38	$ 3.38
Expiration	Dec. 31, 2022	Dec. 31, 2020
Series O [Member]
Shares of Common Stock Issuable from Warrants		618,000	618,000
Weighted Average Exercise Price	$ 3.10	$ 3.10	$ 3.10
Expiration	Oct. 31, 2017	Oct. 31, 2017
Series P [Member]
Shares of Common Stock Issuable from Warrants	306,500	309,000	309,000
Weighted Average Exercise Price	$ 3.70	$ 3.70	$ 3.70
Expiration	Apr. 30, 2018	Apr. 30, 2018
Series Q [Member]
Shares of Common Stock Issuable from Warrants		937,500	937,500
Weighted Average Exercise Price	$ 3.20	$ 3.20	$ 3.20
Expiration	Dec. 31, 2022	Jun. 20, 2019
Series R [Member]
Shares of Common Stock Issuable from Warrants	468,750	937,500	937,500
Weighted Average Exercise Price	$ 4	$ 4	$ 4
Expiration	Dec. 31, 2022	Jun. 20, 2021
Series S-A [Member]
Shares of Common Stock Issuable from Warrants	300,000		300,000
Weighted Average Exercise Price	$ 2.53	$ 2.53	$ 2.53
Expiration	Dec. 31, 2022	Jul. 24, 2022
Series S [Member]
Shares of Common Stock Issuable from Warrants	821,600
Weighted Average Exercise Price	$ 3.42		$ 3.42
Expiration	Sep. 29, 2022

Common Stock and Warrants (De36

Common Stock and Warrants (Details Narrative) - USD ($)	Nov. 03, 2017	Sep. 07, 2017	Jul. 07, 2017	Jan. 05, 2016	Dec. 28, 2017	Nov. 21, 2017	Sep. 29, 2017	Jun. 30, 2017	Nov. 15, 2016	Oct. 30, 2017	Feb. 28, 2018	Feb. 28, 2017	Aug. 31, 2017	Aug. 31, 2016	Apr. 13, 2018	Sep. 11, 2017	Jul. 24, 2017	Mar. 02, 2017	Oct. 07, 2015
Common stock, par value											$ 0.001		$ 0.001	$ 0.001
Common stock, shares authorized											300,000,000		300,000,000	300,000,000
Common stock, shares issued			13,622								36,250,544		34,329,691	28,500,221
Common stock, shares outstanding											36,250,544		34,329,691	28,500,221
Proceeds from issuance of common stock			$ 40,000
Common stock option vested			1,500,000
Common stock issued for services, shares			5,282
Common stock issued for services, value			$ 15,000
Shares reserved for issuance under 2006 Plan											1,035,197		2,072,580
Cashless exercise options													130,000	556,667
Share issued for 2006 Plan to director				30,000
Share issued for director net				90,000		160,000			120,000
Exercise price of share issued to directors				$ 3.75		$ 4.87			$ 3.28
Common stock, shares issued during period						40,000			40,000				46,520	282,106
Proceeds from issuence of units														$ 1,367,100
Number of PPM units exchange for cash														441
Issuance of common stock shares to purchase unit														441,000
Warrant issued under 2013 loan agreement													2,870,739
Convertible debt													$ 3,000,000
Warrant exercised																		5,215,046
Outstanding warrants																		7,642,631
Share based compensation (Monthly)			$ 26,000								$ 1,897,154	$ 530,562	648,201	$ 646,263
Proceeds from exercise of warrants											$ 2,812,426		$ 991,860	$ 4,367,100
Stock purchase option exercised											(276,667)		(130,000)	(556,667)
AlastairLivesey[Member]
Exercise price of share issued to directors						$ 4.87
Common stock, shares issued during period						50,000
Stock issuance lock-in period, description						75% of the 210,000 issued shares are subject to a one-year lock-up
Stock Option [Member]
Cashless exercise options											276,667
Common stock, shares issued during period											141,050
Stock Option [Member] | AlastairLivesey[Member]
Common stock issued for exchange, shares											19,067
Stock purchase option exercised											36,667
Stock Option [Member] | John Conklin [Member]
Common stock issued for exchange, shares											80,110
Stock purchase option exercised											150,000
Three Other Individuals [Member] | Stock Option [Member]
Common stock issued for exchange, shares											41,873
Stock purchase option exercised											90,000
July 2017 Private Placement [Member]
Self directed shares issued																	300,000
Self directed shares issued, per share																	$ 2.30
Self directed shares issued, amount																	$ 690,000
Exercise price of series S-A stock																	$ 2.53
September 2017 Private Placement [Member]
Self directed shares issued							821,600									821,600
Self directed shares issued, per share							$ 3.11									$ 3.11
Self directed shares issued, amount							$ 2,555,176									$ 2,555,176
Exercise price of series S-A stock							$ 3.42
Maturity date							Sep. 29, 2022
June 2016 Private Placement [Member]
Proceeds from issuence of units														$ 3,000,000
Issuance of common stock shares to purchase unit														937,500
Loan Agreement [Member]
Principal loan converted														$ 548,700
Conversion of units under loan agreement														177
Issuance of common stock shares to purchase unit														177,000
Series R [Member] | Third party [Member]
Common stock issued for exchange, shares					285,823
Warrant exercised					468,750
Series I [Member]
Common stock, shares issued													584,634
Description of warrant issued date													Warrant was issued on October 7, 2013, in connection with the 2013 Loan Agreement. On December 31, 2015, as consideration for the Investor agreeing to extend the 2013 Note maturity date to December 31, 2017, the Company extended the maturity date of the Series I Warrant from October 6, 2018 to December 31, 2020.
Commom stock purchase																		921,875
Series J [Member]
Common stock, shares issued													4,293,900
Description of warrant issued date													Warrant were issued on November 10, 2014 as a condition to the Investor entering into the 2015 Loan Agreement. On December 31, 2015, as consideration for the Investor agreeing to extend the 2013 Note maturity date to December 31, 2017, the Company extended the maturity date of the Series J and K Warrants from November 9, 2019 to December 31, 2020.
Commom stock purchase																		3,110,378
Series K [Member]
Common stock, shares issued													4,293,900
Description of warrant issued date													Warrant were issued on November 10, 2014 as a condition to the Investor entering into the 2015 Loan Agreement. On December 31, 2015, as consideration for the Investor agreeing to extend the 2013 Note maturity date to December 31, 2017, the Company extended the maturity date of the Series J and K Warrants from November 9, 2019 to December 31, 2020.
Commom stock purchase																		3,110,378
Series M [Member]
Common stock, shares issued													275,000
Common stock issued for exchange, shares								129,000
Common stock issued for exchange, values								$ 301,860
Description of warrant issued date													An inducement for the Investor to extend the maturity date of the March 2015 Loan from September 4, 2015 to December 21, 2016. In June 2017, the Investor exercised 129,000 Series M Warrants.
Exercise price of warrants								$ 2.34					$ 2.34
Commom stock purchase													100,000
Warrant exercised								129,000					129,000
Series M [Member] | Investor [Member]
Commom stock purchase																			275,000
Series L Warrant [Member]
Common stock, shares issued													336,512
Description of warrant issued date													Warrant was issued on March 4, 2015 in connection with the March 2015 Loan. On December 7, 2015, the expiration date of the Series L Warrant was extended from March 4, 2020 to December 7, 2020.
Series N [Member]
Common stock, shares issued													767,000
Description of warrant issued date													the 2015 Second Amended Loan Agreement as an inducement for the Investor to extend the maturity date of the 2013 Note from December 31, 2015 to December 31, 2017.
Series O [Member]
Common stock issued for exchange, shares										80,000
Description of warrant issued date													The Series O and Series P Warrants were issued in connection with the March 2016 Private Placement and the Series Q and Series R Warrants were issued in connection with the June 2016 Private Placement.
Exercise price of warrants										$ 3.10
Warrant exercised										80,000
Proceeds from exercise of warrants										$ 248,000
Series P [Member]
Description of warrant issued date													The Series O and Series P Warrants were issued in connection with the March 2016 Private Placement and the Series Q and Series R Warrants were issued in connection with the June 2016 Private Placement.
Series P [Member] | Third Holders [Member]
Common stock issued for exchange, shares											2,500
Exercise price of warrants											$ 3.70
Warrant exercised											2,500
Proceeds from exercise of warrants											$ 9,250
Series Q warrants [Member] | Third party [Member]
Common stock issued for exchange, shares		189,940
Warrant exercised		468,750
Series Q warrants [Member] | Investor [Member]
Common stock issued for exchange, shares		189,940
Warrant exercised		468,750
Subsequent Event [Member] | Stock Option [Member]
Common stock, shares issued															5,112
Cashless exercise options											276,667
Subsequent Event [Member] | Series M, N and P [Member] | Warrant [Member]
Shares issuable upon conversion of warrants	213,500
Subsequent Event [Member] | Series R [Member] | Warrant [Member]
Shares issuable upon conversion of warrants	468,750
Subsequent Event [Member] | Series M, N, P, R and S-A [Member] | Warrant [Member]
Maturity date	Dec. 31, 2022
Subsequent Event [Member] | Series Q warrants [Member] | Third party [Member]
Common stock, shares issued		189,940
Subsequent Event [Member] | Series Q warrants [Member] | Investor [Member]
Common stock, shares issued		189,940

Stock Options (Details)

Stock Options (Details) - USD ($)	6 Months Ended		12 Months Ended
	Feb. 28, 2018	Feb. 28, 2017	Aug. 31, 2017	Aug. 31, 2016
Expected dividend yield
Expected stock price volatility				82.00%
Risk-free interest rate				2.06%
Expected term (in years)	7 years 8 months 1 day			7 years 8 months 2 days
Exercise price	$ 5.25	$ 2.71	$ 2.71	$ 3.46
Weighted-average grant date fair-value		$ 1.85	$ 1.85	$ 2.64
Minimum [Member]
Expected stock price volatility	83.43%	79.00%	79.00%
Risk-free interest rate	2.27%	1.95%	1.95%
Expected term (in years)		5 years	5 years
Exercise price	$ 4.87
Weighted-average grant date fair-value	$ 3.76
Maximum [Member]
Expected stock price volatility	83.55%	81.00%	81.00%
Risk-free interest rate	2.33%	2.03%	2.03%
Expected term (in years)		7 years 8 months 1 day	7 years 8 months 2 days
Exercise price	$ 5.35
Weighted-average grant date fair-value	$ 5.64

Stock Options (Details 1)

Stock Options (Details 1) - USD ($)	6 Months Ended		12 Months Ended
	Feb. 28, 2018	Feb. 28, 2017	Aug. 31, 2017	Aug. 31, 2016
Number of Options
Outstanding Beginning	2,125,001	720,001	720,001	1,267,502
Grants	1,263,000		1,535,000	65,000
Forfeitures	300,000			(55,834)
Exercises	(276,667)		(130,000)	(556,667)
Outstanding Ending	2,811,334		2,125,001	720,001
Exercisable Ending	215,334		237,501
Available for grant Ending			2,072,580
Weighted Average Exercise Price ($)
Weighted-average exercise price Beginning	$ 2.84	$ 3.06	$ 3.06	$ 2.68
Grants	5.25	$ 2.71	2.71	3.46
Forfeitures	2.90			3.23
Exercises	3.30		2.62	2.22
Weighted-average exercise price Ending	3.87		2.84	$ 3.06
Exercisable Ending	$ 4.84		$ 3.51
Weighted Average Remaining Contractual Term
Outstanding Ending	6 years 9 months 14 days		5 years 3 months 22 days
Exercisable Ending	8 years 4 months 16 days		6 years 4 days
Aggregate Intrinsic Value ($)
Outstanding Ending	$ 5,154,075		$ 2,969,800
Exercisable Ending	$ 193,975		$ 233,900

Stock Options (Details 2)

Stock Options (Details 2) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2018	Feb. 28, 2017	Feb. 28, 2018	Feb. 28, 2017	Aug. 31, 2017	Aug. 31, 2016
Stock Compensation Expense:
SG&A	$ 181,201	$ 26,667	$ 580,676	$ 79,722	$ 118,969	$ 211,406
R&D	178,980	11,695	293,778	57,240	80,630	97,357
Total	$ 360,181	$ 38,362	$ 874,454	$ 136,962	$ 199,599	$ 308,763

Stock Options (Details 3)

Stock Options (Details 3) - $ / shares	6 Months Ended	12 Months Ended
	Feb. 28, 2018	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Number of Shares Subject to Outstanding Options	2,811,334	2,125,001	720,001	1,267,502
Weighted average contractural life (years)	6 years 9 months 14 days	5 years 3 months 22 days
Weighted-average exercise price	$ 3.87	$ 2.84	$ 3.06	$ 2.68
Number of Shares Subject to options exercisable	215,334	237,501
Weighted average contractural life (years) of options exercisable	8 years 4 months 16 days	6 years 4 days
Weighted-average exercise price of options exercisable	$ 4.84	$ 3.51
$0.80 Per Share [Member]
Number of Shares Subject to Outstanding Options		5,000
Weighted average contractural life (years)		5 years 3 months 22 days
Weighted-average exercise price		$ 0.80
Number of Shares Subject to options exercisable		5,000
Weighted average contractural life (years) of options exercisable		5 years 3 months 22 days
Weighted-average exercise price of options exercisable		$ 0.80
$1.40 Per Share [Member]
Number of Shares Subject to Outstanding Options	1,500,000	5,000
Weighted average contractural life (years)	4 years 4 months 9 days	7 years 3 months 19 days
Weighted-average exercise price	$ 2.70	$ 1.40
Number of Shares Subject to options exercisable		5,000
Weighted average contractural life (years) of options exercisable	4 years 4 months 9 days	7 years 3 months 19 days
Weighted-average exercise price of options exercisable	$ 2.70	$ 1.40
$2.50 Per Share [Member]
Number of Shares Subject to Outstanding Options	217,500	10,000
Weighted average contractural life (years)	9 years 8 months 22 days	3 years 7 months 6 days
Weighted-average exercise price	$ 4.87	$ 2.50
Number of Shares Subject to options exercisable	97,500	10,000
Weighted average contractural life (years) of options exercisable	9 years 8 months 22 days	3 years 7 months 6 days
Weighted-average exercise price of options exercisable	$ 4.87	$ 2.50
$2.70 Per Share [Member]
Weighted average contractural life (years)		5 years
Weighted average contractural life (years) of options exercisable		5 years
$2.90 Per Share [Member]
Number of Shares Subject to Outstanding Options		455,000
Weighted average contractural life (years)		6 years 4 months 28 days
Weighted-average exercise price		$ 2.90
Number of Shares Subject to options exercisable		105,000
Weighted average contractural life (years) of options exercisable		6 years 4 months 28 days
Weighted-average exercise price of options exercisable		$ 2.90
$3.28 Per Share [Member]
Number of Shares Subject to Outstanding Options		35,000
Weighted average contractural life (years)		9 years 2 months 16 days
Weighted-average exercise price		$ 3.28
Number of Shares Subject to options exercisable		17,500
Weighted average contractural life (years) of options exercisable		9 years 2 months 16 days
Weighted-average exercise price of options exercisable		$ 3.28
$3.46 Per Share [Member]
Number of Shares Subject to Outstanding Options	1,008,000	65,000
Weighted average contractural life (years)	9 years 10 months 6 days	8 years 4 months 6 days
Weighted-average exercise price	$ 5.35	$ 3.46
Number of Shares Subject to options exercisable	42,000	45,000
Weighted average contractural life (years) of options exercisable	9 years 10 months 6 days	8 years 4 months 6 days
Weighted-average exercise price of options exercisable	$ 5.35	$ 3.46
$4.98 Per Share [Member]
Number of Shares Subject to Outstanding Options		16,667
Weighted average contractural life (years)		6 months 7 days
Weighted-average exercise price		$ 4.98
Number of Shares Subject to options exercisable		16,667
Weighted average contractural life (years) of options exercisable		6 months 7 days
Weighted-average exercise price of options exercisable		$ 4.98
$5.94 Per Share [Member]
Number of Shares Subject to Outstanding Options		33,334
Weighted average contractural life (years)		3 years 3 months 26 days
Weighted-average exercise price		$ 5.94
Number of Shares Subject to options exercisable		33,334
Weighted average contractural life (years) of options exercisable		3 years 3 months 26 days
Weighted-average exercise price of options exercisable		$ 5.94
$2.70 Per Share [Member]
Number of Shares Subject to Outstanding Options		1,500,000
Weighted-average exercise price		$ 2.70
Number of Shares Subject to options exercisable
Weighted-average exercise price of options exercisable		$ 2.70
$5.94 Per Share [Member]
Number of Shares Subject to Outstanding Options	33,334
Weighted average contractural life (years)	2 years 9 months 25 days
Weighted-average exercise price	$ 5.94
Number of Shares Subject to options exercisable	33,334
Weighted average contractural life (years) of options exercisable	2 years 9 months 25 days
Weighted-average exercise price of options exercisable	$ 5.94
$3.46 Per Share [Member]
Number of Shares Subject to Outstanding Options	35,000
Weighted average contractural life (years)	7 years 10 months 6 days
Weighted-average exercise price	$ 3.46
Number of Shares Subject to options exercisable	25,000
Weighted average contractural life (years) of options exercisable	7 years 10 months 6 days
Weighted-average exercise price of options exercisable	$ 3.46
$3.28 Per Share [Member]
Number of Shares Subject to Outstanding Options	17,500
Weighted average contractural life (years)	8 years 8 months 19 days
Weighted-average exercise price	$ 3.28
Number of Shares Subject to options exercisable	17,500
Weighted average contractural life (years) of options exercisable	8 years 8 months 19 days
Weighted-average exercise price of options exercisable	$ 3.28

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	Jul. 07, 2017	Dec. 27, 2017	Nov. 21, 2017	Aug. 31, 2017	Nov. 15, 2016	Feb. 28, 2018	Aug. 31, 2017	Aug. 31, 2016
Stock option available for grant shares				2,072,580			2,072,580
Stock option exercise				130,000			130,000	1,277,834
Closing stock option exercise price				$ 4.20		$ 5.70	$ 4.20
Stock option outstanding				2,075,000		2,778,000	2,075,000
Stock options granted	1,500,000				35,000
Stock options exercise price	$ 2.70				$ 3.28	$ 5.70	$ 4.20
Expected period for recognition							1 year 6 months
Common stock, shares issued during period			40,000		40,000		46,520	282,106
Aggregate intrinsic value of options						$ 182,000	$ 186,500	$ 1,277,834
Cashless exercise options				130,000			130,000	556,667
Share based compensation (Monthly)	$ 26,000
Common stock option vested	1,500,000
Grant date fair value per option	$ 1.84
Stock option exercise, total						(276,667)	(130,000)	(556,667)
Forfeitures						(300,000)		55,834
Directors and Employees [Member]
Stock options granted			255,000
Stock options exercise price			$ 4.87
Common stock, shares issued during period			50,000
Two Employees [Member]
Stock options granted					35,000
Stock options exercise price					$ 3.28
Employment Agreement [Member]
Stock options granted		1,008,000
Maturity date		Dec. 31, 2017
Vesting rate description		1/48th per month
Forfeitures		300,000
Exercise price		$ 5.35
Stock Option [Member]
Common stock, shares issued during period						141,050
Aggregate intrinsic value of options						$ 1,015,585
Cashless exercise options						276,667
Share based compensation expenses not yet recognized				$ 2,792,847		$ 5,801,820	$ 2,792,847
Share based compensation expenses to be recognized in 1.25 years				32,847		3,041,820	32,847
Conditional share based compensation to be recognized in future				$ 2,760,000		$ 2,760,000	$ 2,760,000
Share based compensation recognition period				1 year 2 months 30 days		4 years
Stock Option [Member] | Directors and Employees [Member]
Stock option exercise, total						36,667
2006 Incentive Stock Option Plan [Member]
Stock option approved				5,000,000		5,000,000	5,000,000
Stock option available for grant shares				2,072,580		1,035,197	2,072,580
Stock option exercise				1,013,334		624,565	1,013,334
Maturity date				Feb. 7, 2021		Feb. 7, 2021
Stock option exercise, total						1,290,001

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2018	Feb. 28, 2017	Feb. 28, 2018	Feb. 28, 2017	Aug. 31, 2017	Aug. 31, 2016
Numerator:
Loss available to common stockholders'	$ (1,489,463)	$ (1,286,271)	$ (4,188,615)	$ (3,008,801)	$ (5,353,425)	$ (4,637,313)
Denominator:
Weighted average number of common shares outstanding	36,135,080	28,666,741	35,743,320	28,615,533	31,299,979	27,295,540
Basic and diluted EPS	$ (0.04)	$ (0.04)	$ (0.12)	$ (0.11)	$ (0.17)	$ (0.17)
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Stock options	2,811,334	625,001	2,811,334	625,001	2,125,001	720,001
Warrants	2,909,850	11,586,631	2,909,850	11,586,631	4,115,000	11,586,631
Convertible debt	3,004,655	2,772,057	3,004,655	2,772,057	2,870,739	2,678,280
Warrants issuable upon conversion of debt (See "NOTE 2 - Debt" above)	3,004,655	2,772,057	3,004,655	2,772,057	2,870,739	2,678,280
Total shares not included in the computation of diluted losses per share	11,730,494	17,755,746	11,730,494	17,755,746	11,981,479	17,663,192

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Nov. 03, 2017USD ($)shares	Nov. 03, 2017USD ($)shares	Aug. 07, 2017USD ($)	Jul. 07, 2017USD ($)shares	Nov. 14, 2016USD ($)	Jul. 24, 2017USD ($)$ / sharesshares	Feb. 28, 2018USD ($)shares	Feb. 28, 2017USD ($)	Feb. 28, 2018USD ($)shares	Feb. 28, 2017USD ($)	Aug. 31, 2017USD ($)shares	Aug. 31, 2016USD ($)shares	Oct. 07, 2017$ / shares	Dec. 31, 2017shares	Mar. 02, 2017shares	Dec. 31, 2016shares	Dec. 31, 2015USD ($)shares	Dec. 22, 2015USD ($)	Oct. 07, 2015USD ($)shares
Outstanding warrants															7,642,631
Issuance of common stock				13,622			36,250,544		36,250,544		34,329,691	28,500,221
Share-based Compensation (monthly) | $				$ 26,000
Ownership percentage							10.00%		10.00%
Debt discount | $							$ 914,762		$ 914,762		$ 413,377	$ 1,650,120					$ 2,476,875
Bridge Loan [Member]
Cash received | $																			$ 550,000
Advance cash received | $																		$ 150,000	400,000
Wire fees | $																			$ 5
Third Amendment to 2013 Bridge Loan Agreement [Member]
Increase in interest rate	10.50%
Maturity date	Dec. 31, 2022
Debt discount | $	$ 1,074,265	$ 1,074,265
Series I [Member]
Commom stock purchase															921,875
Issuance of common stock											584,634
Series I [Member] | December 31 2020 Member
Commom stock purchase											921,875			3,110,378			921,875
Debt discount | $											$ 233,234
Series J [Member]
Commom stock purchase															3,110,378
Issuance of common stock											4,293,900
Series J [Member] | December 31 2020 Member
Commom stock purchase											3,110,378						3,110,378
Debt discount | $											$ 304,817
Series K [Member]
Commom stock purchase															3,110,378
Issuance of common stock											4,293,900
Series K [Member] | December 31 2020 Member
Commom stock purchase											3,110,378			3,110,378			3,110,378
Debt discount | $											$ 326,590
Series L [Member]
Commom stock purchase															500,000
Issuance of common stock															5,215,046
Series N [Member]
Issuance of common stock											767,000
Series N [Member] | December 31 2020 Member
Commom stock purchase											767,000						767,000
Series N [Member] | December 31 2022 Member
Commom stock purchase	767,000	767,000					767,000		767,000
Maturity date									Dec. 31, 2020
Debt discount | $							$ 327,509		$ 327,509
Series M [Member]
Commom stock purchase											100,000
Issuance of common stock											275,000
Series M [Member] | December 31 2022 Member
Commom stock purchase	246,000	246,000					246,000		246,000
Maturity date									Dec. 31, 2020
Debt discount | $							$ 82,656		$ 82,656
Series P [Member] | December 31 2022 Member
Commom stock purchase	213,500	213,500					213,500		213,500
Maturity date									Apr. 30, 2018
Debt discount | $							$ 348,219		$ 348,219
Series R [Member] | December 31 2022 Member
Commom stock purchase	468,750	468,750					468,750		468,750
Maturity date									Jun. 20, 2021
Debt discount | $							$ 295,781		$ 295,781
Series S-A [Member] | December 31 2022 Member
Commom stock purchase	300,000	300,000
Investor [Member]
Short term debt repaid in cash, Advance | $												25,720
Investor [Member] | Third Amendment to 2013 Bridge Loan Agreement [Member]
Terms of agreement		Third Amendment to the 2015 Bridge Loan Agreement, the rate of interest increased to 10.5% and the following warrants, held by the Investor, had their maturity date extended to December 31, 2022: a) Series M Warrant to purchase 246,000 shares; b) Series N Warrant to purchase 767,000 shares; c) Series P Warrant to purchase 213,500 shares; d) Series R Warrant to purchase 468,750; and e) Series S-A Warrant to purchase 300,000 shares
Increase in interest rate		10.50%
Maturity date		Dec. 31, 2019
Debt discount | $	$ 1,074,265	$ 1,074,265
Investor [Member] | Series M [Member]
Commom stock purchase																			275,000
Exercise price | $ / shares													$ 2.34
Investor [Member] | Series M [Member] | December 31 2020 Member
Commom stock purchase																			275,000
Sierchio [Member]
Legal services | $							71,767	$ 45,005	145,834	$ 151,555	$ 321,739	291,951
Satterlee [Member]
Owed amount included in accounts payable | $							71,767		71,767		105,184
March 2015 [Member]
Increase (decrease) in related party payable | $					$ 19,599
Principal amount | $					18,146
Accrued interest | $					$ 1,453
Sierchio & Partners LLP [Member]
Owed amount included in accounts payable | $												53,467
Consulting Agreement [Member]
Related party expense | $							$ 15,000	$ 15,000	$ 30,000	$ 30,000	$ 60,000	$ 60,000
Consulting Agreement [Member] | Mr. Bhogal [Member]
Share-based Compensation (monthly) | $			$ 5,000
Private Placement [Member] | Investor [Member]
Common stock shares reserved for future issuance						300,000
Unit price per share | $ / shares						$ 2.30
Proceeds from units reserved for future issuance | $						$ 690,000
Terms of agreement						Each unit consisted of one share of common stock and one Series S Warrant to purchase one (1) share of common stock at an exercise price of $2.53 per share through July 24, 2022. The warrants may be exercised on a cashless basis.
Private Placement [Member] | Series S Warrant [Member] | Investor [Member]
Exercise price | $ / shares						$ 2.53
March 2016 Private Placement [Member] | Investor [Member]
Issuance of common stock																427,000
Conversion of units under loan agreement																177
Number of units purchased												250
Principal loan converted | $												$ 548,700
Proceed from private placement | $												$ 775,000
March 2016 Private Placement [Member] | Series O [Member] | Investor [Member]
Outstanding warrants																427,000
March 2016 Private Placement [Member] | Series P [Member] | Investor [Member]
Outstanding warrants																213,500
June 2016 Private Placement [Member] | Investor [Member]
Issuance of common stock												468,750
Number of units purchased												468,750
Proceed from private placement | $												$ 1,500,000
June 2016 Private Placement [Member] | Series Q [Member] | Investor [Member]
Issuance of common stock												468,750
June 2016 Private Placement [Member] | Series R [Member] | Investor [Member]
Issuance of common stock												468,750

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Aug. 31, 2017	Aug. 31, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 7,120,032	$ 5,995,528
Capitalized research and development	1,431,748	1,285,254
Depreciation	(7,137)	(82)
Stock based compensation	1,168,629	1,207,988
Foreign affiliate interest expense	296,315	190,173
Research and development credit carry forward	438,298	369,117
Total deferred tax assets	10,447,885	9,047,979
Less: valuation allowance	(10,447,885)	(9,047,979)
Net deferred tax asset

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Income Taxes Details 1
Income tax benefit at statutory rate	$ 1,820,165	$ 1,576,686
Permanent differences	(490,980)	(297,211)
Research and development credit	70,721	63,323
Change in valuation allowance	(1,399,906)	(1,342,798)
Total

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Income Taxes Details Narrative
Change in valuation allowance	$ 1,399,906	$ 1,342,798
Research and development credit carry forward	438,298	$ 369,117
Federal income tax	$ 20,941,270
Federal income tax expire period	August 31, 2020 to August 31, 2037

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Apr. 13, 2018	Mar. 03, 2018	Nov. 03, 2017	Sep. 11, 2017	Jul. 07, 2017	Feb. 28, 2018	Sep. 07, 2017	Aug. 31, 2017	Aug. 31, 2016
Stock option exercise								130,000	1,277,834
Issuance of common stock					13,622	36,250,544		34,329,691	28,500,221
Proceeds from issuance of common stock					$ 40,000
Cashless exercise options								130,000	556,667
Stock Option [Member]
Cashless exercise options						276,667
2013 Bridge Loan Agreement [Member] | Investor [Member]
Maturity date			Dec. 31, 2019
2015 Bridge Loan Agreement [Member] | Investor [Member]
Interest rate increase			10.50%
Maturity date			Dec. 31, 2019
Subsequent Event [Member] | Stock Option [Member]
Stock option exercise	15,000
Issuance of common stock	5,112
Cashless exercise options						276,667
Subsequent Event [Member] | Two other employees [Member]
Stock option exercise							72,500
Issuance of common stock							33,151
Subsequent Event [Member] | John Conklin [Member]
Stock option exercise							100,000
Issuance of common stock							46,097
Subsequent Event [Member] | September 2017 Private Placement [Member]
Self directed shares issued				821,600
Self directed shares issued, per share				$ 3.11
Self directed shares issued, amount				$ 2,555,176
Exercise price				$ 3.42
Description Subscription agreements				The unit price was based on a 15% discount to the average of the 30 day closing price (last day being Friday September 8, 2017) of the Company’s common stock as reported on the OTCQB. Each unit consisted of one share of common stock and one Series S Stock Purchase Warrant to purchase one (1) share of common stock at an exercise price of $3.42 per share through September 29, 2017.
Subsequent Event [Member] | Series P [Member]
Stock option exercise	1,000	500
Issuance of common stock	500	500
Exercise price	$ 3.70	$ 3.70
Proceeds from issuance of common stock	$ 3,700	$ 1,850
Subsequent Event [Member] | Series O [Member] | September 2017 Private Placement [Member]
Stock option exercise				80,000
Warrants Purchase				80,000
Exercise price				$ 3.10
Proceeds from issuance of common stock				$ 248,000
Subsequent Event [Member] | Third Amendment 2015 Bridge Loan Agreement [Member]
Interest rate increase			10.50%
Maturity date			Dec. 31, 2022
Subsequent Event [Member] | Third Amendment 2015 Bridge Loan Agreement [Member] | Series R [Member]
Warrants Purchase								468,750
Subsequent Event [Member] | Third Amendment 2015 Bridge Loan Agreement [Member] | Series P [Member]
Warrants Purchase								213,500
Subsequent Event [Member] | Third Amendment 2015 Bridge Loan Agreement [Member] | Series N [Member]
Warrants Purchase								767,000
Subsequent Event [Member] | Third Amendment 2015 Bridge Loan Agreement [Member] | Series M [Member]
Warrants Purchase								246,000
Subsequent Event [Member] | 2013 Bridge Loan Agreement [Member] | Investor [Member]
Maturity date			Dec. 31, 2019
Subsequent Event [Member] | 2015 Bridge Loan Agreement [Member] | Investor [Member]
Maturity date			Dec. 31, 2019
Subsequent Event [Member] | Series S-A [Member] | Third Amendment 2015 Bridge Loan Agreement [Member]
Warrants Purchase								300,000
Subsequent Event [Member] | Series Q [Member] | Third party [Member]
Issuance of common stock							189,940
Warrants Purchase							468,750
Subsequent Event [Member] | Series Q [Member] | Investor [Member]
Issuance of common stock							189,940
Warrants Purchase							468,750